[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"University of Utah\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":580},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,146,0,25,[9,43,65,90,112,133,152,183,209,231,253,277,296,318,339,360,393,411,438,457,478,502,521,540,559],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100054284","early-phase-1-metformin-and-aclr-muscle-recovery-100054284",false,"NCT07699367","Metformin and ACLR Muscle Recovery","Metformin and Muscle Recovery Following ACL Surgery","Inclusion Criteria:\n\n1. Age between 40y and older\n2. BMI: \\\u003C30 kg\u002Fm2\n3. Full thickness ACL tear\n4. Less than 6 months between ACL injury and scheduled ACLR\n\nExclusion Criteria:\n\n1. Prior ACL tear in limb scheduled for reconstruction or current bilateral ACL tear\n2. Total knee dislocation\n3. Anticipated quadriceps ACLR grafts\n4. Current infection near the lower limb\n5. Inability to attend physical therapy sessions\n6. Post-operative loading restrictions\n7. History of cardiovascular disease (e.g., CHF, CAD, MI, CVA)\n8. History of endocrine or metabolic disease such as hypo\u002Fhyperthyroidism and diabetes (Treated hypo\u002Fhyperthyroid for at least 6 months will be permitted)\n9. History of stroke with motor disability\n10. History of respiratory disease (acute upper respiratory infection, history of chronic lung disease)\n11. Self-reported pregnancy\n12. Bleeding disorder\n13. Implanted electronic devices (e.g., pacemakers, electronic infusion pumps, stimulators)\n14. Cancer or history of successfully treated cancer (less than 1 year) other than basal cell carcinoma\n15. Chronic systemic corticosteroid use (≥ 2 weeks) within 4 weeks of enrollment and for study duration (intra-articular\u002Ftopical\u002Finhaled therapeutic or physiologic doses of corticosteroids will be permitted)\n16. Androgens or growth hormone within 6 months of enrollment and for study duration (topical physiologic androgen replacement will be permitted)\n17. Currently taking estrogen products (topical estrogen products will be permitted)\n18. Taking anticoagulant medication (warfarin\u002FCoumadin, heparin) that may complicate the muscle biopsy\n19. Any staff members who report directly to the principal investigators","ALL","40 Years",{"count":20,"type":21},40,"ESTIMATED","INTERVENTIONAL",[24],"EARLY_PHASE1","The purpose of this research study is to determine if Metformin taken after anterior cruciate ligament reconstruction (ACLR) surgery can decrease muscle fibrosis, cellular senescence and improve leg strength. ACL injury and surgery increase muscle collagen content and inflammation which slows the recovery of muscle and function and ultimately impacts the quality of life. Individuals enrolled in the study will be randomized to receive metformin (or placebo) for 4 months after surgery. The investigators will measure muscle strength and inflammatory markers in muscle biopsy samples after the intervention period. Investigators will also follow up with participants 8 months later to determine the lasting effects of the intervention.",[27,28,29],"Atrophy","Inflammation","Weakness, Muscle","NOT_YET_RECRUITING","2026-07-09",{"date":33,"type":34},"2026-07-13","ACTUAL",{"date":36,"type":21},"2026-11-01",{"date":38,"type":21},"2032-10-01",{"name":40,"class":41},"University of Utah","OTHER",1,{"id":44,"slug":45,"hasResults":12,"nctId":46,"briefTitle":47,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":12,"sex":17,"minAge":50,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":22,"phases":53,"briefSummary":55,"conditions":56,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":42},"100054243","ai-driven-survivorship-care-plans-ai-scp-100054243","NCT07700199","AI-Driven Survivorship Care Plans (AI-SCP)","AI-SCP","Inclusion Criteria:\n\n* Adult cancer survivors\n* Age +18 years,\n* Speak and understand English\n* Affiliated with the Huntsman Cancer Institute.\n\nExclusion Criteria:\n\n* Under age 18\n* Not affiliated with Huntsman Cancer Institute\n* Unable to speak or understand English","18 Years",{"count":52,"type":21},50,[54],"NA","This project conducts exploratory work on a HIPAA-compliant, large language model (LLM)-based tool that integrates structured and unstructured oncology electronic health record (EHR) data to automate the development of tailored SCPs, paired with a patient-facing chatbot to answer questions about the SCP. Unlike generic AI documentation tools, this system establishes benchmarks for SCP development and embeds user-centered design (UCD) directly into prompt engineering and model governance workflows.",[57],"Cancer","2026-07-07",{"date":33,"type":34},{"date":61,"type":21},"2026-08-01",{"date":63,"type":21},"2027-08",{"name":40,"class":41},{"id":66,"slug":67,"hasResults":12,"nctId":68,"briefTitle":69,"officialTitle":69,"acronym":4,"eligibilityCriteria":70,"healthyVolunteers":12,"sex":17,"minAge":71,"maxAge":72,"enrollmentInfo":73,"targetDuration":4,"studyType":22,"phases":75,"briefSummary":76,"conditions":77,"keywords":79,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":42},"100053905","digital-technology-informed-stroke-rehabilitation-100053905","NCT07698522","Digital Technology-Informed Stroke Rehabilitation","Inclusion Criteria:\n\n* Age between 30-85 years.\n* Diagnosis of stroke.\n* Stroke onset of at least six months prior to the time of participation.\n* Fugl Meyer Upper Extremity between 30-50 (mild-moderate)\n* Cognitive skills to consent and actively participate, as indicated by scores of ≥ 24 on the Mini- Mental Status Examination\n* Able to visit lab up to 5x per week for 3 weeks\n\nExclusion Criteria:\n\n* Presence of severe aphasia preventing the ability to follow 1-step directions at least 80% of the time.\n* Excessive spasticity of the wrist, elbow, and shoulder, defined as a Modified Ashworth Score \\>2.\n* Diagnosis of neurological disorders other than stroke.\n* Orthopedic\u002Fmusculoskeletal conditions (e.g., severe arthritis) affecting the upper extremity.\n* Currently or planning to become pregnant.\n* Participation in concurrent occupational therapy.\n* Unilateral neglect, defined as failure of the Line Bisection Task\n* Upper extremity pain \\>= 7\u002F10 on Numeric Rating Scale","30 Years","85 Years",{"count":74,"type":21},60,[54],"The goal of this study is to determine the effects of lab and home-based technology guidance during movement training post-stroke. The study will compare movement training informed by lab-based technology to training delivered with technology at home. The main questions it aims to answer are:\n\n* How well do lab and home-based technologies help individuals post-stroke improve their movement patterns?\n* Is there a difference in improvement between the in-lab and at-home training groups?\n* Which technologies lead to the most improvement?",[78],"Stroke",[80,81,82],"movement training","rehabilitation","occupational therapy","2026-07-06",{"date":33,"type":34},{"date":86,"type":21},"2026-07",{"date":88,"type":21},"2033-12",{"name":40,"class":41},{"id":91,"slug":92,"hasResults":12,"nctId":93,"briefTitle":94,"officialTitle":95,"acronym":96,"eligibilityCriteria":97,"healthyVolunteers":12,"sex":17,"minAge":50,"maxAge":4,"enrollmentInfo":98,"targetDuration":4,"studyType":22,"phases":99,"briefSummary":101,"conditions":102,"keywords":4,"overallStatus":104,"whyStopped":4,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":108,"completionDateStruct":109,"leadSponsor":111,"locationsCount":42},"100544187","phase-2-neoadjuvant-ipilimumabnivolumab-for-patients-with-recurrent-high-risk-resectable-melanoma-100544187","NCT06365619","Neoadjuvant Ipilimumab\u002FNivolumab for Patients With Recurrent, High Risk, Resectable Melanoma","Phase II Study of Neoadjuvant Ipilimumab\u002FNivolumab for Patients With Recurrent, High Risk, Resectable Melanoma","NeoRelapse","Inclusion Criteria:\n\n* Subjects aged ≥ 18 years.\n* Histologically confirmed Stage IIIB-D or Stage IV recurrent metastatic melanoma that is resectable or borderline resectable as determined by a Surgical Oncologist.\n* Recurrent disease at eligibility must have been confirmed with biopsy after receiving prior anti-PD1 based systemic therapy (either adjuvant, neoadjuvant, or definitive therapy).\n* ECOG Performance Status ≤ 1.\n* Adequate organ function as defined as:\n\n  * Hematologic:\n\n    * Absolute neutrophil count (ANC) ≥ 1500\u002Fmm3\n    * Platelet count ≥ 100,000\u002Fmm3\n    * Hemoglobin ≥ 10 g\u002FdL\n  * Hepatic:\n\n    * Total Bilirubin ≤ 1.5x institutional upper limit of normal (ULN)\n    * AST(SGOT)\u002FALT(SGPT) ≤ 3 × institutional ULN\n\n      * Subjects with liver metastases will be allowed to enroll with AST and ALT levels ≤ 5 x ULN.\n  * Renal:\n\n    * Estimated creatinine clearance ≥ 50 mL\u002Fmin by Cockcroft-Gault formula:\n* For subjects of childbearing potential: Negative pregnancy test or evidence of post-menopausal status or evidence of permanent surgical sterilization. The post-menopausal status will be defined as having been amenorrheic for 12 months without an alternative medical cause. The following age-specific requirements apply:\n\n  * Subjects \\\u003C 50 years of age:\n\n    * Amenorrheic for ≥ 12 months following cessation of exogenous hormonal treatments; and\n    * Luteinizing hormone and follicle-stimulating hormone levels in the post-menopausal range for the institution\n  * Subjects ≥ 50 years of age:\n\n    * Amenorrheic for ≥ 12 months following cessation of all exogenous hormonal treatments; or\n    * Had radiation-induced menopause with last menses \\>1 year ago; or\n    * Had chemotherapy-induced menopause with last menses \\>1 year ago\n* Subjects of childbearing potential and subjects with a sexual partner of childbearing potential must agree to use a highly effective method of contraception.\n* Recovery to baseline or ≤ Grade 1 CTCAE v5 from toxicities related to any prior treatments, unless AE(s) are clinically nonsignificant and\u002For stable on supportive therapy per the treating investigator.\n* Able to provide informed consent and willing to sign an approved consent form that conforms to federal and institutional guidelines.\n\nExclusion Criteria:\n\n* Prior exposure to anti-CTLA4 therapy.\n* Receiving other investigational agents currently or within 28 days of study treatment.\n* Prior systemic anti-cancer therapy ≤ 14 days or within five half-lives prior to starting study treatment, whichever is shorter.\n* Prior radiotherapy 45 days prior to the first dose of study treatment.\n* Major surgery 4 weeks prior to starting study drug or who have not fully recovered from major surgery.\n* Active infection requiring the use of systemic antibiotics.\n* Systemic steroid therapy greater than physiologic equivalent (10mg prednisone\u002Fday) or any other form of systemic immunosuppressive therapy within 7 days prior to registration.\n* Active secondary malignancy, unless the malignancy is not expected to interfere with the evaluation of safety\n* Known brain metastases or cranial epidural disease.\n* Current evidence of uncontrolled, significant intercurrent illness including, but not limited to, the following conditions:\n\n  * Cardiovascular disorders:\n\n    * Congestive heart failure New York Heart Association Class III or IV, unstable angina pectoris, serious cardiac arrhythmias.\n    * Stroke (including transient ischemic attack \\[TIA\\]), myocardial infarction (MI), or other ischemic events, or thromboembolic event (eg, deep venous thrombosis, pulmonary embolism) within 3 months before the first dose.\n    * QTc prolongation defined as a QTcF \\> 500 ms.\n    * Known congenital long QT.\n    * Left ventricular ejection fraction \\\u003C 55%.\n    * Uncontrolled hypertension defined as ≥ 140\u002F90 as assessed from the mean of three consecutive blood pressure measurements taken over 10 minutes.\n  * Any other condition that would, in the Investigator's judgment, contraindicate the subject's participation in the clinical study due to safety concerns or compliance with clinical study procedures (e.g., infection\u002Finflammation, intestinal obstruction, unable to swallow medication, \\[subjects may not receive the drug through a feeding tube\\], social\u002Fpsychological issues, etc.)\n* HIV infection with a detectable viral load within 6 months of the anticipated start of treatment.\n\n  --Note: Subjects on effective antiretroviral therapy with an undetectable viral load within 6 months of the anticipated start of treatment are eligible for this trial.\n* Active infection including tuberculosis (clinical evaluation that includes clinical history, physical examination, radiographic findings, and TB testing in line with local practice), hepatitis B (positive HBV surface antigen (HBsAg) result), or hepatitis C.\n\n  --Note: Subjects with a past or resolved HBV infection (defined as the presence of hepatitis B core antibody \\[anti-HBc\\] and absence of HBsAg) are eligible. Subjects positive for hepatitis C (HCV) antibody are eligible only if polymerase chain reaction is negative for HCV RNA.\n* Medical, psychiatric, cognitive, or other conditions that may compromise the subject's ability to understand the subject information, give informed consent, comply with the study protocol or complete the study.\n* Known prior severe hypersensitivity to investigational product (IP) or any component in its formulations (NCI CTCAE v5.0 Grade ≥ 3).\n* Subjects taking prohibited medications as described in Section 6.7.2. A washout period of prohibited medications for a period of at least five half-lives or as clinically indicated should occur before the start of treatment.",{"count":7,"type":21},[100],"PHASE2","The goal of this clinical trial is to study the impact of Neoadjuvant ipilimumab and nivolumab for melanoma patients that had recurrence during or after adjuvant anti-PD-1 therapy.\n\nParticipants will receive 2 cycles of treatment prior to their standard of care surgery. After surgery participants will receive standard of care adjuvant therapy and be followed for response.",[103],"Melanoma","RECRUITING","2026-06-30",{"date":107,"type":34},"2026-07-02",{"date":86,"type":21},{"date":110,"type":21},"2030-08",{"name":40,"class":41},{"id":113,"slug":114,"hasResults":12,"nctId":115,"briefTitle":116,"officialTitle":116,"acronym":117,"eligibilityCriteria":118,"healthyVolunteers":12,"sex":17,"minAge":50,"maxAge":4,"enrollmentInfo":119,"targetDuration":4,"studyType":22,"phases":121,"briefSummary":123,"conditions":124,"keywords":4,"overallStatus":104,"whyStopped":4,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":127,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":42},"100533531","phase-1-pilot-study-of-anti-cd19-chimeric-antigen-receptor-t-cells-car-t-cells-for-the-treatment-of-relapsedrefractory-cd19-malignancies-100533531","NCT06227026","Pilot Study of Anti-CD19 Chimeric Antigen Receptor T Cells (CAR-T Cells) for the Treatment of Relapsed\u002FRefractory CD19+ Malignancies","PRODIGY","Inclusion Criteria:\n\n* Subjects aged ≥ 18 years.\n* Histologically confirmed relapsed or refractory CD-19+ malignancy, including: non-Hodgkin lymphoma (NHL), acute lymphoblastic leukemia (ALL), Chronic Lymphocytic Leukemia (CLL)\u002FRichter's syndrome. CD-19+ must be confirmed by immunohistochemistry or flow cytometry analysis.\n* Subjects who have relapsed or refractory disease after failing at least 2 or more prior lines of therapy.\n* ECOG Performance Status ≤ 2.\n* Life expectancy \\> 12 weeks.\n* Willing to consent to 15 years of follow-up as part of IRB 110692: Long-Term Evaluation of the Biology and Outcomes of Hematopoietic Stem Cell Transplantation\n* Adequate organ function as defined as:\n\n  * Hematologic:\n\n    * Absolute neutrophil count (ANC) ≥ 500\u002Fmm3\n    * Platelet count ≥ 10,000\u002Fmm3\n    * Hemoglobin ≥ 8 g\u002FdL\n  * Hepatic:\n\n    * Total Bilirubin ≤ 1.5x institutional upper limit of normal (ULN).\n    * AST(SGOT)\u002FALT(SGPT) ≤ 3 × institutional ULN\n  * Renal:\n\n    * Serum Creatinine ≤ 2 x institutional upper limit of normal (ULN) or eGFR \\>30 ml\u002Fmin\u002F1.73m2\n* For subjects of childbearing potential: Negative pregnancy test or evidence of post-menopausal status or evidence of permanent surgical sterilization. The post-menopausal status will be defined as having been amenorrheic for 12 months without an alternative medical cause. The following age-specific requirements apply:\n\n  * Subjects \\\u003C 50 years of age:\n\n    * Amenorrheic for ≥ 12 months following cessation of exogenous hormonal treatments; and\n    * Luteinizing hormone and follicle-stimulating hormone levels in the post-menopausal range for the institution\n  * Subjects ≥ 50 years of age:\n\n    * Amenorrheic for 12 months or more following cessation of all exogenous hormonal treatments; or\n    * Had radiation-induced menopause with last menses \\>1 year ago; or\n    * Had chemotherapy-induced menopause with last menses \\>1 year ago\n* Subjects of childbearing potential and subjects with a sexual partner of childbearing potential must agree to use a highly effective method of contraception as described in Section 5.4.1.\n* Recovery to baseline or ≤ Grade 2 CTCAE v5.0 from toxicities related to any prior cancer therapy, unless considered stable by the treating investigator.\n* Adequate venous access.\n* Able to provide informed consent and willing to sign an approved consent form that conforms to federal and institutional guidelines.\n* Step 2 Eligibility Confirmation\n\n  * The following criteria must be confirmed within 7 days prior to lymphodepletion. If all criteria are not met, lymphodepletion should be delayed.\n\n    * Confirmation of successful CAR-T manufacturing.\n    * No evidence or suspicion of an infection.\n    * Serum Creatinine ≤ 2 x institutional upper limit of normal (ULN) or eGFR \\>30 ml\u002Fmin\u002F1.73m2\n    * No worsening of clinical status compared to either the initial eligibility criteria that would, in the opinion of the treating physician, significantly increase the risk from lymphodepleting chemotherapy or exclude them from treatment with study CAR-T therapy.\n* Step 3 Eligibility Confirmation\n\n  * The following criteria must be confirmed prior to CAR-T therapy. If all criteria are not met, CAR-T therapy should be delayed.\n\n    * No worsening of clinical status compared to either the initial eligibility criteria that would, in the opinion of the treating physician, significantly increase the risks from treatment with CAR-T therapy.\n    * Confirmation that washout periods outlined in section 6.6 and Appendix 10 have been followed.\n\nExclusion Criteria:\n\n* Autologous or allogeneic stem cell transplant or CAR-T therapy within 6 weeks of planned CAR-T cell infusion.\n* Subjects with active infection that requires systemic treatment\n* History of autoimmune disease (i.e. rheumatoid arthritis, systemic lupus erythematosus) with requirement of immunosuppressive medication within 6 months.\n* Pregnant or breastfeeding women are excluded from this study because CAR-T cell therapy may be associated with the potential for teratogenic or abortifacient effects. Women of child bearing potential must have a negative serum pregnancy test. Because there is an unknown, but potential risk for adverse events in nursing infants secondary to treatment of the mother with CAR-T cells, breastfeeding should be discontinued. These potential risks may also apply to other agents used in this study.\n* Receiving other investigational agents.\n* Confirmation that washout periods listed in Appendix 10 have been followed.\n* Major surgery 4 weeks prior to starting study drug or who have not fully recovered from major surgery.\n* The diagnosis of another malignancy within ≤ 2 years before study enrollment, except for those considered to be adequately treated with no evidence of disease or symptoms and\u002For will not require therapy during the study duration (i.e., basal cell or squamous cell skin cancer, carcinoma in situ of the breast, bladder or of the cervix, or low-grade prostate cancer with Gleason Score ≤ 6). Patients with transformed disease are allowed.\n* Known brain metastases or cranial epidural disease. Note: Brain metastases or cranial epidural disease adequately treated with radiotherapy and\u002For surgery and stable for at least 4 weeks before the first dose of study treatment will be allowed on trial. Subjects must be neurologically asymptomatic and without corticosteroid treatment at the time of the first dose of study treatment.\n* Current evidence of uncontrolled, significant intercurrent illness including, but not limited to, the following conditions:\n\n  * Cardiovascular disorders:\n\n    * Congestive heart failure New York Heart Association Class III or IV, unstable angina pectoris, serious cardiac arrhythmias.\n    * Stroke (including transient ischemic attack \\[TIA\\]), myocardial infarction (MI), or other ischemic events, or thromboembolic event (e.g., deep venous thrombosis, pulmonary embolism) within 3 months before the first dose.\n    * QTc prolongation defined as a QTcF \\> 500 ms.\n    * Known congenital long QT.\n    * Left ventricular ejection fraction \\\u003C 55%.\n    * Uncontrolled hypertension defined as ≥ 140\u002F90 as assessed from the mean of three consecutive blood pressure measurements taken over 10 minutes.\n  * Any other condition that would, in the Investigator's judgment, contraindicate the subject's participation in the clinical study due to safety concerns or compliance with clinical study procedures (e.g., infection\u002Finflammation, intestinal obstruction, unable to swallow medication, \\[subjects may not receive the drug through a feeding tube\\], social\u002F psychological issues, etc.)\n* Active infection including tuberculosis (clinical evaluation that includes clinical history, physical examination, radiographic findings, and TB testing in line with local practice), hepatitis B (known positive HBV surface antigen (HBsAg) result), hepatitis C, or seropositive HIV. Note: Subjects with a past or resolved HBV infection (defined as the presence of hepatitis B core antibody \\[anti-HBc\\] and absence of HBsAg) are eligible. Subjects positive for hepatitis C (HCV) antibody are eligible only if polymerase chain reaction is negative for HCV RNA.\n* Medical, psychiatric, cognitive, or other conditions that may compromise the subject's ability to understand the subject information, give informed consent, comply with the study protocol or complete the study.\n* Known prior severe hypersensitivity to investigational product (IP) or any component in its formulations (NCI CTCAE v5.0 Grade ≥ 3).\n* Subjects taking prohibited medications as described in Section 6.6 and Appendix 10. Unless otherwise stated, a washout period of prohibited medications for a period of at least five half-lives or as clinically indicated should occur before the start of treatment.\n* Subjects with history of clinically relevant CNS pathology such as epilepsy, seizure disorders, paresis, aphasia, uncontrolled cerebrovascular disease, severe brain injuries, dementia and Parkinson's disease.",{"count":120,"type":21},10,[122],"PHASE1","This is an open label, non-randomized, phase 1 study of anti-CD19 CAR-T cells against relapsed CD19 positive NHL, CLL and ALL based in a lymphodepletion regimen (fludarabine and cyclophosphamide) and using a CellReGen-based process for manufacturing CAR-T cells.\n\nThis study will utilize a staggered enrollment design with a safety observation period.",[125,126],"Acute Lymphoblastic Leukemia","Diffuse Large B Cell Lymphoma",{"date":107,"type":34},{"date":129,"type":34},"2024-02-20",{"date":131,"type":21},"2027-05",{"name":40,"class":41},{"id":134,"slug":135,"hasResults":12,"nctId":136,"briefTitle":137,"officialTitle":138,"acronym":4,"eligibilityCriteria":139,"healthyVolunteers":12,"sex":17,"minAge":50,"maxAge":4,"enrollmentInfo":140,"targetDuration":4,"studyType":22,"phases":142,"briefSummary":143,"conditions":144,"keywords":4,"overallStatus":104,"whyStopped":4,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":146,"startDateStruct":147,"completionDateStruct":149,"leadSponsor":151,"locationsCount":42},"100239086","phase-1-stereotactic-radiosurgery-dose-escalation-for-brain-metastases-100239086","NCT02390518","Stereotactic Radiosurgery Dose Escalation for Brain Metastases","Phase I Study of Stereotactic Radiosurgery Dose Escalation for Brain Metastases","Inclusion Criteria:\n\n* Clinically confirmed brain metastases by CT or MRI criteria. If there is evidence of extra-cranial metastatic disease, it is preferable that the lesions be pathologically confirmed (see section 4.2.5 for excluded histologies) and reviewed by a University of Utah or Huntsman Cancer Hospital pathologist if the initial review was done at an outside facility.\n* Prior brain surgery is allowed, although a lesion situated in the operative bed would not be selected to receive an experimental dose of SRS treatment. SRS should be delivered 4-6 weeks post-surgery if the patient had a craniotomy for resection of a lesion. Enrollment of a patient with the goal of performing SRS outside of the 4-6 post-craniotomy window is at the PI's discretion.\n* Patients must have 1-5 untreated brain metastases total.\n* For patients planning to enroll in Cohort 1a (including expansion) or Cohort 1b: Tumor volume ≤ 4.1888 cm3 by CT or MRI measurement at the time of consultation\u002Fscreening for the metastatic lesion on trial. Patients who have at least one additional lesion that is larger than the lesions eligible for the expansion cohort, but who are unable to find another open cohort, will have the eligible lesion(s) treated in the expansion cohort, and the remaining lesion(s) treated at the standard dose.\n\n  * For patients enrolling in the expansion Cohort 1a: Up to five brain metastases with tumor volume ≤ 0.5237 cm3 by CT or MRI measurement at the time of consultation\u002Fscreening will be treated on trial with the MTD. Brain metastases with volume \\> 0.5237 cm3 will be treated by standard of care SRS dosing.\n  * For patients enrolling in Cohort 1b: Tumor volume of \\> 0.5237 cm3 and ≤ 4.1888 cm3 by CT or MRI measurement at the time of consultation\u002Fscreening for the metastatic lesion on trial. All other brain metastases will be treated by standard of care SRS dosing.\n* As of Protocol Version 9, Cohorts 2 and 3 are permanently closed to accrual. For patients planning to enroll in Cohort 2 or 3: Equivalent tumor diameter ≤ 40 mm by CT or MRI measurement at the time of consultation\u002Fscreening for the metastatic lesion on trial. Equivalent tumor diameter \\\u003C\u002F=40 mm by CT or MRI measurement for all lesions treated by standard of care SRS dosing.\n* All metastatic lesions must be separated by a minimum of 3 cm as measured from the peripheral edges of the lesions that are in closest proximity to one another. If multiple lesions are present and are not all ≥ 3 cm away from each other, the patient will be deemed ineligible.\n* Prior systemic therapy is allowed, although appropriate washout is required for patients who have been on BRAF inhibitors (at least 7 days).\n* For subjects currently on active systemic cancer therapy, the treating medical oncologist should be consulted to ensure proper washout (if appropriate) periods prior to SRS.\n* Patients must be at least 18 years of age.\n* Karnofsky Performance Status (KPS) ≥ 60.\n* Able to provide informed consent and have signed an approved consent form that conforms to federal and institutional guidelines.\n* Women of child-bearing potential must have a negative pregnancy test within 10 days of study enrollment and must agree to use an acceptable method of birth control while receiving radiation and for 3 months after radiation. Women of non-childbearing potential may be included if they are either surgically sterile or have been postmenopausal for \\>1 year.\n* Men who are able to father a child must agree to use an acceptable method of birth control while receiving radiation, and for 3 months after radiation.\n\nExclusion Criteria:\n\n* Prior whole brain irradiation.\n* Brain lesions with an equivalent diameter of \\> 40 mm in size on MRI imaging at the time of consultation\u002Fscreening for protocol eligibility.\n* Lesions located in anatomic regions that are not amendable to SRS (e.g., optic nerve)\n* Brain lesions located in the brain stem.\n* Radiographic or cytologic evidence of leptomeningeal disease\n* Primary lesion with radiosensitive histology that includes the following: small cell carcinoma, germ cell tumors, lymphoma, leukemia, or multiple myeloma\n* Women of child-bearing potential who are pregnant or breast feeding\n* Patients with multiple lesions, which by size criteria would be enrolled in a cohort that is full at the time of enrollment and the 12-16 weeks DLT period has not yet been reached.",{"count":141,"type":21},86,[122],"This is a Phase I dose escalation and expansion trial. The purpose of this study is to determine the maximum tolerated dose of radiation received during stereotactic radiosurgery in patients with brain metastases who have never received radiation to the brain before.",[145],"Brain Metastases",{"date":107,"type":34},{"date":148,"type":34},"2015-05-07",{"date":150,"type":21},"2029-10",{"name":40,"class":41},{"id":153,"slug":154,"hasResults":12,"nctId":155,"briefTitle":156,"officialTitle":157,"acronym":158,"eligibilityCriteria":159,"healthyVolunteers":12,"sex":160,"minAge":50,"maxAge":4,"enrollmentInfo":161,"targetDuration":4,"studyType":163,"phases":4,"briefSummary":164,"conditions":165,"keywords":170,"overallStatus":104,"whyStopped":4,"lastUpdateSubmitDate":175,"lastUpdatePostDateStruct":176,"startDateStruct":178,"completionDateStruct":180,"leadSponsor":182,"locationsCount":42},"100573527","culturally-engaged-recovery-moms-connected-through-native-community-100573527","NCT06747442","Culturally Engaged REcovery: MOms Connected Through Native communitY","Culturally Engaged REcovery - MOms Connected Through Native communitY (CEREMONY)","CEREMONY","CEREMONY Inclusion Criteria:\n\n* English or Spanish speaking\n* pregnant (verified by point of care urine pregnancy test)\n* plan to carry the fetus to delivery\n* identify as Indigenous, Native, Native American, American Indian or Alaska Native\n* willing to grant a release of information to allow study staff to contact other health care institutions and treatment centers and collect information from the medical record, e.g., date of delivery, infant admission etc.\n\nCEREMONY Exclusion Criteria:\n\n* have a documented psychotic episode in the last 30 days\n* be \\>39 weeks of gestation\n* be unable provide collateral contact information of at least 1 person\n* be unable to provide reliable phone number\n* plan to move within 3 months of delivery","FEMALE",{"count":162,"type":21},270,"OBSERVATIONAL","Pregnant and postpartum American Indian and Alaska Native people (Native mothers) face a more than two-fold higher risk of maternal mortality compared to non-Hispanic White mothers. Deaths related to substance use (SU) and mental health conditions are a leading cause of preventable maternal mortality, including among Native mothers, making these conditions a strong target for reducing maternal mortality and morbidity. The objective of this study is to 1) adapt evidence-based perinatal care models that integrate pregnancy and postpartum care with SU treatment and care to meet the needs of Native mothers, and 2) assess the implementation and efficacy of that model for participants with substance use disorder who identify as Native receiving prenatal care at Sacred Circle Healthcare in Salt Lake City, Utah.",[166,167,168,169],"Substance Use Disorders (SUD)","Pregnancy","Maternal Morbidity and Mortality","Cultural Adaptation",[167,171,172,173,174],"Prenatal care","Substance Use Disorder","Native and Indigenous Health","Culturally adapted care","2026-06-27",{"date":177,"type":34},"2026-07-01",{"date":179,"type":34},"2026-05-26",{"date":181,"type":21},"2029-03",{"name":40,"class":41},{"id":184,"slug":185,"hasResults":12,"nctId":186,"briefTitle":187,"officialTitle":188,"acronym":189,"eligibilityCriteria":190,"healthyVolunteers":191,"sex":17,"minAge":192,"maxAge":193,"enrollmentInfo":194,"targetDuration":4,"studyType":22,"phases":195,"briefSummary":196,"conditions":197,"keywords":4,"overallStatus":104,"whyStopped":4,"lastUpdateSubmitDate":202,"lastUpdatePostDateStruct":203,"startDateStruct":204,"completionDateStruct":206,"leadSponsor":208,"locationsCount":42},"100645236","financial-counseling-for-dementia-family-caregivers-in-early-and-middle-adulthood-100645236","NCT07681401","Financial Counseling for Dementia Family Caregivers in Early and Middle Adulthood","Financial Counseling and Advocacy for Alzheimer's Disease and Related Dementias Family Caregivers in Early and Middle Adulthood","FCA 4 FC-EAMA","Inclusion Criteria:\n\n* Caring for a family member, neighbor, or friend with ADRD\n* Providing care for 20 or more hours per week,\n* Technology access for Zoom visits\n* English speaking\n\nExclusion Criteria:\n\n* N\u002FA",true,"25 Years","55 Years",{"count":120,"type":21},[54],"The goal of this National Institutes of Health (NIH) Stage 1a study is to develop and pilot test a research- and community-informed financial counseling and advocacy (FCA) intervention for dementia family caregivers in early and middle adulthood. The main question it aims to answer is:\n\nIs a research- and community-informed financial counseling and advocacy intervention usable, feasible and acceptable for dementia family caregivers in early and middle adulthood?\n\nParticipants will engage in a four-week single group financial counseling and advocacy intervention and complete pre- and post-intervention measures addressing financial well-being, caregiver strain, workplace productivity, and flourishing along with usability, acceptability, and feasibility measures.",[198,199,200,201],"Family Caregivers","Dementia","Financial Wellbeing","Financial Coaching","2026-06-25",{"date":107,"type":34},{"date":205,"type":34},"2026-04-10",{"date":207,"type":21},"2026-10",{"name":40,"class":41},{"id":210,"slug":211,"hasResults":12,"nctId":212,"briefTitle":213,"officialTitle":214,"acronym":215,"eligibilityCriteria":216,"healthyVolunteers":12,"sex":217,"minAge":50,"maxAge":4,"enrollmentInfo":218,"targetDuration":4,"studyType":22,"phases":220,"briefSummary":221,"conditions":222,"keywords":4,"overallStatus":104,"whyStopped":4,"lastUpdateSubmitDate":202,"lastUpdatePostDateStruct":224,"startDateStruct":226,"completionDateStruct":228,"leadSponsor":230,"locationsCount":42},"100559778","phase-2-xl092-in-patients-with-metastatic-castration-resistant-prostate-cancer-100559778","NCT06568562","XL092 in Patients With Metastatic Castration-Resistant Prostate Cancer","PRO-XL: A Phase II Study of XL092 in Patients With Metastatic Castration-Resistant Prostate Cancer After Progression on Lutetium-177 (177Lu)-PSMA-617","PRO-XL","Inclusion Criteria:\n\n* Participant aged ≥ 18 years\n* Disease criteria:\n\n  --Histologically or cytologically confirmed prostatic adenocarcinoma without small cell histology\n  * Radiographic evidence of metatstatic disease\n  * Progression on or after prior treatment with 177Lu-PSMA-617 as determined by clinical investigator\n* ECOG Performance Status ≤ 2.\n* Adequate organ function as defined as:\n\n  * Absolute neutrophil count ≥ 1500\u002Fmm3 .\n  * Platelet count ≥ 100,000\u002Fmm3 .\n  * Hemoglobin ≥ 9 g\u002FdL .\n  * Total Bilirubin ≤ 1.5x institutional ULN. For subject's with Gilbert's disease, ≤ 3 x ULN.\n  * Alanine aminotransferase (ALT), aspartate aminotransferase (AST), and alkaline phosphatase (ALP) ≤ 3 x ULN. For subjects with documented bone metastasis ALP ≤ 5 x ULN. For subjects with CRPC and bone metastasis ALP ≤ 10 x ULN if predominantly bone-specific ALP.\n  * International Normalized Ratio (INR) ≤ 1.5 and activated partial thromboplastin time (aPTT) ≤ 1.2 upper limit of normal (ULN)\n  * Serum creatinine ≤ 1.5 x ULN or estimated creatinine clearance ≥ 40 mL\u002Fmin by Cockcroft-Gault formula:\n\n    ---Males: ((140-age)×weight\\[kg\\])\u002F(serum creatinine \\[mg\u002FdL\\]×72)\n  * Urine protein-to-creatinine ratio (UPCR) ≤ 1.5 mg\u002Fmg (≤ 169.8 mg\u002Fmmol) creatinine or 24-hour urine protein \\\u003C1.5 g.\n* Sexually active fertile subjects and their partners must agree to use highly effective method of contraception (defined in Section 5.4.1) during the course of the study and for 96 days after the last dose of treatment (whichever is later). An additional contraceptive method, such as a barrier method (eg, condom), is required. In addition, men must agree not to donate sperm for the purpose of reproduction during these same periods.\n* Must have recovered from adverse effects of any prior oncologic treatment (e.g. prior surgery, radiotherapy, or other antineoplastic therapy). CTCAE adverse events less than or equal to grade 1 are acceptable. CTCAE adverse events grade 2 or greater may be acceptable as determined by the Clinical Investigator.\n* Able to provide informed consent and willing to sign an approved consent form that conforms to federal and institutional guidelines.\n\nExclusion Criteria:\n\n* Prior treatment with XL092\n* Receipt of any type of small molecule kinase inhibitor, cytotoxic, biologic or other systemic anticancer therapy (including investigational) within 2 weeks or at least 5 half-lives, whichever shorter before first dose of study treatment.\n\nNote: Concomitant use of megestrol acetate, androgen-deprivation therapy and bone loss prevention treatment is permitted. Other types of hormonal therapies with similar use require prior approval from the Principal Investigator.\n\n* Radiation therapy for bone metastasis or any other radiation therapy within 2 weeks before first dose of study treatment. Subjects with clinically relevant ongoing complications from prior radiation therapy are not eligible.\n* Known brain metastases or cranial epidural disease unless adequately treated with radiotherapy and\u002For surgery (including radiosurgery) and stable for at least 4 weeks before first dose of study treatment.\n\nNote: Subjects with an incidental finding of an isolated brain lesion \\\u003C 1 cm in diameter may be eligible after Principal Investigator approval if the lesion is radiographically stable for 4 weeks before first dose and does not require treatment per Investigator judgement.\n\nNote: Eligible subjects must be neurologically asymptomatic and without corticosteroid treatment at the time of first dose of study treatment.\n\n-Concomitant anticoagulation with oral anticoagulants except for those specified below:-\n\n* (a) Prophylactic use of low-dose aspirin for cardioprotection (per local applicable guidelines), low-dose low molecular weight heparins (LMWH) or prophylactic dose of specified direct factor Xa inhibitors rivaroxaban, edoxaban, or apixaban\n* (b) Therapeutic doses of LMWH or specified direct factor Xa inhibitors rivaroxaban, edoxaban, or apixaban in subjects without known brain metastases who are on a stable dose of the anticoagulant for at least 1 week before enrollment and without clinically significant hemorrhagic complications from the anticoagulation regimen or the tumor.\n\n  * Any complementary medications (eg, herbal supplements or traditional Chinese medicines) to treat the disease under study within 2 weeks or at least 5 half-lives, whichever shorter before first dose of study treatment.\n  * The subject has uncontrolled, significant intercurrent or recent illness including, but not limited to, the following conditions:\n* Cardiovascular disorders:\n\n  * Congestive heart failure New York Heart Association Class 3 or 4, unstable angina pectoris, serious cardiac arrhythmias \\[eg, ventricular flutter, ventricular fibrillation, Torsades de pointes (TdP)\\].\n  * Uncontrolled hypertension defined as sustained blood pressure (BP) \\> 140 mm Hg systolic or \\> 90 mm Hg diastolic despite optimal antihypertensive treatment.\n  * Stroke (including transient ischemic attack \\[TIA\\]), myocardial infarction, or other clinically significant ischemic event within 6 months before first dose of study treatment.\n  * Pulmonary embolism (PE) or deep vein thrombosis (DVT) or prior clinically significant venous or non-CVA\u002FTIA arterial thromboembolic events within 3 months before to first dose of study treatment.\n\nNote: Subjects with a diagnosis of DVT within 3 months are allowed if asymptomatic and stable at screening and treated with anticoagulation per standard of care before first dose of study treatment.\n\nNote: Subjects who don't require prior anticoagulation therapy may be eligible but must be discussed and approved by the Principal Investigator.\n\n--Gastrointestinal (GI) disorders including those associated with a high risk of perforation or fistula formation:\n\n* Tumors invading the GI-tract from external viscera, tumors invading respiratory tracts\n* Active peptic ulcer disease, inflammatory bowel disease including, ulcerative colitis or Crohn's disease, diverticulitis, cholecystitis, symptomatic cholangitis or appendicitis, or acute pancreatitis\n* Acute obstruction of the bowel, gastric outlet, or pancreatic or biliary duct within 6 months unless cause of obstruction is definitively managed and subject is asymptomatic\n* Abdominal fistula, gastrointestinal perforation, bowel obstruction, or intra-abdominal abscess within 6 months before first dose. Note: Complete healing of an intra-abdominal abscess must be confirmed before first dose of study treatment.\n* Known gastric or esophageal varices\n* Abdominal\u002Fperitoneal carcinomatosis\n* Active perianal abscess\n* History of pelvic or abdominal perforation\n* History of bowel resection unless determined to be low risk of perforation by clinical investigator\n* History of radiation therapy to the abdomen unless determined to be low risk of perforation by clinical investigator\n* Prior GI surgery (particularly when associated with delayed or incomplete healing) unless completely healed and determined to be low risk of perforation by clinical investigator\n\n  * Clinically significant hematuria, hematemesis, or hemoptysis of \\> 0.5 teaspoon (2.5 ml) of red blood, or other history of significant bleeding (eg, pulmonary hemorrhage) within 12 weeks before first dose of study treatment.\n  * Cavitating pulmonary lesion(s) or known endotracheal or endobronchial disease manifestation.\n  * Lesions invading major blood vessel including, but not limited to, inferior vena cava, pulmonary artery, or aorta.\n\nNote: Subjects with intravascular tumor extension (eg, tumor thrombus in renal vein or inferior V. cava) may be eligible following Principal Investigator approval.\n\n* Other clinically significant disorders that would preclude safe study participation.\n\n  * Active infection requiring systemic treatment. Note: Prophylactic antibiotic treatment is allowed.\n  * Known infection with acute or chronic hepatitis B or C, known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)-related illness.\n  * Known positive test for or suspected infection with clinically significant SARS-CoV-2 within one month before enrollment. Note: demonstration that the subject has fully recovered from the infection as determined by clinical investigator is required to be eligible for enrollment\n  * Serious non-healing wound\u002Fulcer\u002Fbone fracture. Note: non-healing wounds or ulcers are permitted if due to tumor-associated skin lesions.\n  * Malabsorption syndrome.\n  * Pharmacologically uncompensated, symptomatic hypothyroidism.\n  * Moderate to severe hepatic impairment (Child-Pugh B or C).\n  * Requirement for hemodialysis or peritoneal dialysis.\n  * History of solid organ or allogeneic stem cell transplant.\n* Major surgery (as defined in Appendix B; eg, GI surgery, removal or biopsy of brain metastasis) within 8 weeks prior to first dose of study treatment. Prior laparoscopic nephrectomy within 4 weeks prior to first dose of study treatment. Minor surgery (eg, simple excision, tooth extraction) within 10 days before first dose of study treatment. Complete wound healing from major or minor surgery must have occurred at least prior to first dose of study treatment.\n\nNote: Fresh tumor biopsies should be performed at least 7 days before the first dose of study treatment. Subjects with clinically relevant ongoing complications from prior surgical procedures, including biopsies, are not eligible.\n\n-Corrected QT interval calculated by the Fridericia formula (QTcF) \\> 480 ms for males within 14 days per electrocardiogram (ECG) before first dose of study treatment.\n\nNote: Triplicate ECG evaluations will be performed and the average of these 3 consecutive results for QTcF will be used to determine eligibility.\n\n* History of psychiatric illness likely to interfere with ability to comply with protocol requirements or give informed consent.\n* Inability to swallow tablets.\n* Previously identified allergy or hypersensitivity to components of the study treatment formulations.\n* Any other active malignancy or diagnosis of another malignancy within 2 years before first dose of study treatment requiring systemic treatment, except for superficial skin cancers, or localized, low grade tumors deemed cured and not treated with systemic therapy.\n\nNote: Patients with prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial as approved by the Principal Investigator.\n\n* Other conditions, which in the opinion of the Investigator, would compromise the safety of the patient or the patient's ability to complete the study.\n* Participants taking prohibited medications as described in Section 6.8. A washout period of prohibited medications for a period of at least five half-lives or as clinically indicated should occur before the start of treatment.","MALE",{"count":219,"type":21},32,[100],"The purpose of this study is to determine how well the study drug XL092 is helping to treat a participant's cancer after 16 weeks of treatment. Researchers will also look at how safe the XL092 is and how well the XL092 is working. XL092 is an oral tablet that will be taken once a day. Participants will return to clinic for regular visits for checkups and tests.",[223],"Metastatic Castration-resistant Prostate Cancer",{"date":225,"type":34},"2026-06-29",{"date":227,"type":34},"2024-12-09",{"date":229,"type":21},"2028-12",{"name":40,"class":41},{"id":232,"slug":233,"hasResults":12,"nctId":234,"briefTitle":235,"officialTitle":236,"acronym":237,"eligibilityCriteria":238,"healthyVolunteers":12,"sex":17,"minAge":50,"maxAge":4,"enrollmentInfo":239,"targetDuration":4,"studyType":22,"phases":241,"briefSummary":242,"conditions":243,"keywords":4,"overallStatus":104,"whyStopped":4,"lastUpdateSubmitDate":245,"lastUpdatePostDateStruct":246,"startDateStruct":247,"completionDateStruct":249,"leadSponsor":251,"locationsCount":252},"100562775","phase-1-loncastuximab-tesirine-and-rituximab-following-stereotactic-radiosurgery-in-patients-with-central-nervous-system-lymphomas-solar-100562775","NCT06607549","Loncastuximab Tesirine and Rituximab Following Stereotactic Radiosurgery in Patients With Central Nervous System Lymphomas (SOLAR)","A Phase 1 Study of Loncastuximab Tesirine and Rituximab Following Stereotactic Radiosurgery (SRS) in Patients With Primary and Secondary Central Nervous System Lymphomas","SOLAR","Inclusion Criteria:\n\n* Participant aged ≥ 18 years\n* ECOG Performance Status ≤ 3\n* Histologically confirmed primary CNS lymphoma or secondary diffuse large B-cell lymphoma (DLBCL) with CNS involvement with either:\n\n  * Relapsed or refractory disease with at least 1 prior therapy OR\n  * Ineligible for high-dose methotrexate-based therapy as determined by the treating physician, including previously untreated patients. Examples of medical conditions for which a patient could be considered ineligible for high-dose methotrexate include but not limited to renal impairment, liver disease, heart failure.\n\n    * Note: For patients with a history of histologically documented systemic DLBCL with CNS relapse, a biopsy of the CNS lesion is recommended but not required.\n* Must be a candidate for SRS. Lesion size must be \\\u003C 6 cm and the number of lesions must be \\\u003C 10.\n* Must have evaluable disease. This includes radiographic evidence of parenchymal disease or parenchymal disease and disease detected in the CSF.\n\n  * Patients with vitreous or retinal involvement alone are not eligible.\n  * Patients with leptomeningeal disease or spinal cord disease are not eligible.\n* Adequate organ function as defined as:\n\n  * Hematologic:\n\n    * Absolute neutrophil count ≥ 1000 cells\u002Fmm3 (1.00 x 109\u002FL) independent of G-CSF support (i.e. no G-CSF within the past 3 days) unless there is documented bone marrow involvement.\n    * Platelet count ≥ 75,000 cells\u002Fmm3 (75 x 109\u002FL) independent of transfusion support (i.e. no transfusion within the past 3 days) unless there is documented bone marrow involvement.\n    * Hemoglobin ≥ 8 g\u002FdL (≥ 80 g\u002FL) independent of transfusion support (i.e. no transfusion within the past 3 days) unless there is documented bone marrow involvement.\n  * Hepatic:\n\n    ---Total bilirubin ≤ 2.0 mg\u002FdL (unless bilirubin rise is due to Gilbert's syndrome), if total bilirubin is \\> 2.0 mg\u002FdL, the subject is eligible for the study if the direct bilirubin is normal; transaminases (AST\u002FALT) ≤2.5 x upper limit of normal (ULN) AST(SGOT)\u002FALT(SGPT) ≤ 3 × institutional ULN\n  * Renal:\n\n    * Estimated creatinine clearance ≥ 30 mL\u002Fmin by Cockcroft-Gault formula:\n\n      * Males: ((140-age)×weight\\[kg\\])\u002F(serum creatinine \\[mg\u002FdL\\]×72)\n      * Females: (((140-age)×weight\\[kg\\])\u002F(serum creatinine \\[mg\u002FdL\\]×72))×0.85\n* For subjects of childbearing potential: Negative pregnancy test or evidence of permanent surgical sterilization. The post-menopausal status will be defined as having been amenorrheic for 12 months without an alternative medical cause. The following age-specific requirements apply:\n\n  * \\\u003C 50 years of age:\n\n    * Amenorrheic for ≥ 12 months following cessation of exogenous hormonal treatments; and\n    * Luteinizing hormone and follicle-stimulating hormone levels in the post-menopausal range for the institution\n  * ≥ 50 years of age:\n\n    * Amenorrheic for 12 months or more following cessation of all exogenous hormonal treatments; or\n    * Had radiation-induced menopause with last menses \\>1 year ago; or\n    * Had chemotherapy-induced menopause with last menses \\>1 year ago\n* Female participants of childbearing potential must agree to use a highly effective method of contraception as described in Section 5.4.1 until 10 months after last dose of loncastuximab tesirine and 12 months after the last dose of rituximab. Male participants with female partners of childbearing potential must agree to use a highly effective method of contraception when sexually active until 7 months after the last dose of loncastuximab tesirine.\n* Provide written informed consent and comply with the study protocol as judged by the Investigator. Of note, if the subject has an impairment that prevents him\u002Fher from providing consent, the site may follow approved institutional procedures for obtaining consent. The investigator should document when a potential or current participant lacks decision-making capacity and thus requires an LAR to provide consent.\n\nExclusion Criteria:\n\n* Concurrent use of other approved or investigational antineoplastic agents (with the exception of corticosteroids).\n* History of intracranial hemorrhage or clinically significant stroke within 6 months prior to enrollment\n* History of prior radiation to the CNS.\n* Significant medical diseases or conditions, as assessed by the investigator, that would substantially increase the risk-to-benefit ratio of participating in the study. This includes, but is not limited to, acute myocardial infarction in the past 6 months, unstable angina, uncontrolled diabetes mellitus, significant active infections, severely immunocompromised state, and congestive heart failure, New York Heart Association Class III-IV.\n* Known bleeding diathesis (e.g., von Willebrand's disease), hemophilia, or active bleeding.\n* Known Human immunodeficiency virus (HIV) infection.\n* Prior allogeneic stem cell transplant (autologous stem cell transplant is NOT an exclusion).\n* Prior exposure to loncastuximab tesirine\n* Chemotherapy or targeted small molecule therapy (or other therapy for CNS lymphoma) within 3 weeks prior to the first day of study treatment (or 5 half-lives (whichever is shorter), or 2 weeks prior to the first day of study treatment for monoclonal antibodies.\n* The patient must have recovered to baseline or ≤ grade 1 from prior toxicities of therapy with the exception of alopecia and myelosuppression provided lab criteria met. Recovery to ≤ grade 2 neuropathy is permitted.\n* Cellular therapy within 8 weeks.\n* Presence of clinically significant pericardial or pleural effusions, or third space fluid accumulations (i.e., ascites requiring drainage or pleural effusion that is either requiring drainage or associated with shortness of breath).\n* Congenital long QT syndrome or a corrected QT measure (QTc) interval of \\>480 ms at screening (unless secondary to pacemaker or bundle branch block).\n* Known history of hypersensitivity to CD19 antibody and\u002For, components of study medication.\n* All subjects must be screened for hepatitis B and C. Patients with evidence of active hepatitis B infection, based on positive surface antigen or Hepatitis B DNA PCR are excluded. Patients who are Hepatitis B core antibody positive must take prophylaxis with entecavir or equivalent and be willing to undergo monthly Hepatitis B DNA PCR testing. Subjects with active Hep C patients may be enrolled if other parameters precluding hepatic impairment are met and they are not undergoing active therapy for hepatitis C.\n* Active systemic bacterial, viral, fungal, or other infection requiring systemic treatment at time of screening.\n* Subjects with chronic liver disease with hepatic impairment Child-Pugh class C\n* Pregnant or lactating or intending to become pregnant during the study.\n* Patients diagnosed with another malignancy within three years or with any evidence of residual prior malignant disease (except nonmelanoma skin cancer, non-metastatic prostate cancer, in situ cervical cancer, or ductal or lobular carcinoma in situ). Patients meeting this exclusion criteria may be enrolled after approval from study PI.\n* Unable to tolerate corticosteroids",{"count":240,"type":21},12,[122],"The purpose of this clinical trial is to learn if drugs loncastuximab tesirine and rituximab (lonca-R) after stereotactic radiosurgery are safe and effective for treatment of central nervous system lymphomas.",[244],"Central Nervous System Lymphoma","2026-06-24",{"date":225,"type":34},{"date":248,"type":34},"2025-03-18",{"date":250,"type":21},"2030-11",{"name":40,"class":41},3,{"id":254,"slug":255,"hasResults":12,"nctId":256,"briefTitle":257,"officialTitle":258,"acronym":4,"eligibilityCriteria":259,"healthyVolunteers":12,"sex":17,"minAge":50,"maxAge":4,"enrollmentInfo":260,"targetDuration":4,"studyType":22,"phases":262,"briefSummary":263,"conditions":264,"keywords":266,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":269,"lastUpdatePostDateStruct":270,"startDateStruct":272,"completionDateStruct":274,"leadSponsor":276,"locationsCount":4},"100644297","focus-pre-post-study-100644297","NCT07664514","FOCUS Pre-Post Study","Facilitating Goal-based Conversations for Understanding Surgery (FOCUS) Guide: Pre-Post Study","Inclusion Criteria:\n\nFor surgeons\n\n1\\. Surgeons who have regular outpatient clinics at the University of Utah and Huntsman Cancer Institute\n\nFor patients:\n\n1. Age ≥65 years.\n2. Presenting for in-person outpatient consultation regarding major non-urgent surgery with an enrolled surgeon.\n3. Ability to provide informed consent.\n4. English-speaking.\n\nExclusion Criteria:\n\nFor surgeons\n\n1. Surgeons with a predominantly pediatric practice\n2. Transplant surgeons\n\nFor patients\n\n1. Anticipated life expectancy \\\u003C3 months.\n2. Inability to complete study procedures.\n3. Patients presenting for minor procedures or non-operative consultations.\n4. Telehealth consultation\n5. Any clinical, cognitive, communication, or logistical factor that, in the opinion of the treating surgeon or investigator, would substantially interfere with participation or completion of study procedures.",{"count":261,"type":21},180,[54],"The Facilitating Goal-based Conversations for Understanding Surgery (FOCUS) Guide is a communication intervention designed to support discussion and documentation of the goal for surgery during outpatient surgical consultations. The purpose of this study is to assess the efficacy of the FOCUS guide in prompting discussion of the goal for surgery.",[265],"Surgery",[265,267,268],"Goals","Communication guide","2026-06-23",{"date":271,"type":34},"2026-06-26",{"date":273,"type":21},"2026-08-15",{"date":275,"type":21},"2029-05",{"name":40,"class":41},{"id":278,"slug":279,"hasResults":12,"nctId":280,"briefTitle":281,"officialTitle":282,"acronym":4,"eligibilityCriteria":283,"healthyVolunteers":12,"sex":17,"minAge":50,"maxAge":4,"enrollmentInfo":284,"targetDuration":4,"studyType":22,"phases":286,"briefSummary":287,"conditions":288,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":269,"lastUpdatePostDateStruct":291,"startDateStruct":292,"completionDateStruct":293,"leadSponsor":295,"locationsCount":42},"100644976","brief-postoperative-pain-management-intervention-meaning-making-amendment-100644976","NCT07676500","Brief Postoperative Pain Management Intervention: Meaning Making Amendment","Brief Postoperative Pain Management Intervention for Knee and Hip Replacement Patients: Meaning Making Amendment","Inclusion Criteria:\n\n* Age ≥18,\n* Underwent joint arthroplasty of the knee or hip\n\nExclusion Criteria:\n\n* Inability to read English\n* Cognitive impairment preventing completion of study procedures",{"count":285,"type":21},576,[54],"This single-site, two-arm, parallel-group randomized controlled trial will enroll adults undergoing total knee or hip replacement surgery. Two days after surgery, participants will complete a brief guided mindful breathing practice delivered by text message and will then be randomized to receive either personalized meaning-making questions or implementation-focused questions. The trial will evaluate whether personalized meaning-making questions enhance the clinical effects of the mindfulness practice on acute pain, pain unpleasantness, anxiety, desire for pain medication.",[289,290],"Pain, Acute","Anxiety Acute",{"date":105,"type":34},{"date":177,"type":21},{"date":294,"type":21},"2027-09-30",{"name":40,"class":41},{"id":297,"slug":298,"hasResults":12,"nctId":299,"briefTitle":300,"officialTitle":300,"acronym":4,"eligibilityCriteria":301,"healthyVolunteers":191,"sex":160,"minAge":50,"maxAge":4,"enrollmentInfo":302,"targetDuration":4,"studyType":22,"phases":304,"briefSummary":305,"conditions":306,"keywords":4,"overallStatus":104,"whyStopped":4,"lastUpdateSubmitDate":312,"lastUpdatePostDateStruct":313,"startDateStruct":314,"completionDateStruct":316,"leadSponsor":317,"locationsCount":42},"100502797","optimizing-cardiovascular-preventive-care-for-women-following-hypertensive-disorders-of-pregnancy-100502797","NCT05826925","Optimizing Cardiovascular Preventive Care for Women Following Hypertensive Disorders of Pregnancy","Inclusion Criteria:\n\n* Delivered a pregnancy complicated by a hypertensive disorder of pregnancy at the University of Utah during the current hospital admission\n* Ability to speak and read English or Spanish\n* Written informed consent obtained\n\nExclusion Criteria:\n\n* Cardiovascular disease diagnosis (history of peripheral artery disease, stroke, or myocardial infarction)\n* Impairment of cognitive function or vision that prohibits communication and\u002For reading the decision aid.",{"count":303,"type":21},30,[54],"Cardiovascular disease is the leading cause of death among women in the United States, and women with hypertensive disorders of pregnancy have a 2-fold higher risk for cardiovascular disease later in life compared to women with uncomplicated pregnancies. This research investigates a patient-centered intervention during the postpartum period to promote engagement in cardiovascular preventive care.",[307,308,309,310,311],"Hypertension, Pregnancy Induced","Hypertension Complicating Pregnancy","Preeclampsia","Cardiovascular Diseases","Patient Engagement","2026-06-22",{"date":269,"type":34},{"date":315,"type":21},"2026-07-15",{"date":63,"type":21},{"name":40,"class":41},{"id":319,"slug":320,"hasResults":12,"nctId":321,"briefTitle":322,"officialTitle":323,"acronym":324,"eligibilityCriteria":325,"healthyVolunteers":12,"sex":217,"minAge":50,"maxAge":4,"enrollmentInfo":326,"targetDuration":4,"studyType":22,"phases":328,"briefSummary":329,"conditions":330,"keywords":4,"overallStatus":104,"whyStopped":4,"lastUpdateSubmitDate":332,"lastUpdatePostDateStruct":333,"startDateStruct":334,"completionDateStruct":336,"leadSponsor":338,"locationsCount":42},"100609566","phase-2-optimal-psa-triggered-individual-management-of-androgen-sensitive-prostate-cancer-100609566","NCT07216248","Optimal PSA Triggered Individual Management of Androgen Sensitive Prostate Cancer","A Phase II Randomized, Decentralized, De-escalation Study in Patients With Metastatic Hormone-Sensitive Prostate Cancer Achieving Optimal PSA Response (OPTIMAS)","OPTIMAS","Inclusion Criteria:\n\nCohort A Eligibility (Step 1 Registration)\n\n* Participant aged ≥ 18 years\n* Hormone-sensitive prostate cancer with histologically\u002Fcytologically confirmed adenocarcinoma without small cell histology.\n* Metastasis detected any time prior to study registration on conventional or functional imaging as determined by the treating investigator and can be of any site.\n* Baseline testosterone \\>50 ng\u002Fdl before start of therapy for metastatic disease\n* PSA ≥ 1 ng\u002FmL before start of therapy for metastatic disease\n* ECOG Performance Status ≤ 2\n* Eligible to receive standard of care treatment with relugolix and APRI per clinical investigator.\n* Participants with a sexual partner of childbearing potential must agree to use a highly effective method of contraception requirements as described in Section 5.5.1.\n\n  * If the risk of seminal transfer from the participant is present, the participant must agree to use a condom during sexual intercourse as described in Section 5.5.2.\n  * Participants must agree not to donate sperm from the start of study therapy until 3 months after the last dose of study therapy.\n* Clinically significant adverse effects from any prior oncologic treatment (e.g. prior surgery, radiotherapy, or other antineoplastic therapy) must have resolved or have been determined to be clinically stable per the Investigator.\n* Has access to a smartphone and wireless services and is able to download and navigate study specific applications.\n* Able to provide informed consent and willing to sign an approved consent form that conforms to federal and institutional guidelines.\n\nCohort A Eligibility (Step 2 Registration) -PSA ≤ 0.2 ng\u002FmL after 6-12 months of relugolix and androgen receptor pathway inhibitor treatment. Androgen receptor pathway inhibitor includes abiraterone, enzalutamide, apalutamide, darolutamide or similar drugs.\n\nCohort B Eligibility\n\n* Participant aged ≥ 18 years\n* Hormone-sensitive prostate cancer with histologically\u002Fcytologically confirmed adenocarcinoma without small cell histology.\n* Metastasis detected any time prior to study registration on conventional or functional imaging as determined by clinical investigator and can be of any site.\n* PSA ≤ 0.2 ng\u002FmL after treatment with androgen deprivation therapy or androgen receptor pathway inhibitor treatment or both of any duration. Androgen deprivation therapy in this context includes gonadotropin-releasing hormone agonists and antagonists. Androgen receptor pathway inhibitors include abiraterone, enzalutamide, apalutamide, darolutamide or similar drugs.\n* Eligible to receive standard of care treatment with relugolix and APRI per clinical investigator.\n* Participants with a sexual partner of childbearing potential must agree to use a highly effective method of contraception requirements as described in Section 5.5.1.\n\n  * If the risk of seminal transfer from the participant is present, the participant must agree to use a condom during sexual intercourse as described in Section 5.5.2.\n  * Participants must agree not to donate sperm from the start of study therapy until 3 months after the last dose of study therapy.\n* Has access to a smartphone and wireless services and is able to download and navigate study specific applications.\n* Able to provide informed consent and willing to sign an approved consent form that conforms to federal and institutional guidelines.\n\nExclusion Criteria:\n\nCohort A Eligibility (Step 1 Registration)\n\n* Participant received androgen deprivation therapy (defined as leuprolide or surgical castration) for metastatic hormone-sensitive prostate cancer.\n* The diagnosis of another malignancy which, in the opinion of the Investigator, is likely to negatively impact the participant's safety or ability to participate in the study.\n* Known brain metastases or cranial epidural disease.\n\n  --Note: Brain metastases or cranial epidural disease adequately treated with radiotherapy and\u002For surgery and stable for at least 4 weeks before the first dose of study treatment will be allowed on trial. Participants must be neurologically stable and receiving a stable or decreasing corticosteroid dose at the time of study entry.\n* Current evidence of uncontrolled, significant intercurrent illness, infection, non-compliance or other safety concerns which may affect clinical trial participation.\n* Medical, psychiatric, cognitive, or other conditions that may compromise the participant's ability to understand the participant information, give informed consent, comply with the study protocol or complete the study.\n* Known prior severe hypersensitivity to investigational product or any component in its formulations (CTCAE v5.0 Grade ≥ 3).\n* Participants taking prohibited medications as described in Section 6.6.2.\n\nCohort A Eligibility (Step 2 Registration)\n\n* Receiving other systemic anti-cancer therapy for prostate cancer. Prior treatment before Step 2 registration is allowed.\n* Progression to metastatic castration-resistant prostate cancer per clinical investigator.\n* The diagnosis of another malignancy which, in the opinion of the Investigator, is likely to negatively impact the participant's safety or ability to participate in the study.\n* Participants taking prohibited medications as described in Section 6.6.2.\n\nCohort B Eligibility\n\n* Receiving other systemic anti-cancer therapy for prostate cancer.\n* History of surgical castration.\n* The diagnosis of another malignancy which, in the opinion of the Investigator, is likely to negatively impact the participant's safety or ability to participate in the study.\n* Known brain metastases or cranial epidural disease.\n\n  --Note: Brain metastases or cranial epidural disease adequately treated with radiotherapy and\u002For surgery and stable for at least 4 weeks before the first dose of study treatment will be allowed on trial. Participants must be neurologically stable and receiving a stable or decreasing corticosteroid dose at the time of study entry\n* Current evidence of uncontrolled, significant intercurrent illness, infection, compliance or other safety concerns which may affect clinical trial participation.\n* Medical, psychiatric, cognitive, or other conditions that may compromise the participant's ability to understand the participant information, give informed consent, comply with the study protocol or complete the study.\n* Known prior severe hypersensitivity to investigational product or any component in its formulations (CTCAE v5.0 Grade ≥ 3).\n* Participants taking prohibited medications as described in Section 6.6.1.",{"count":327,"type":21},160,[100],"The purpose of this study is to evaluate intermittent relugolix + androgen receptor pathway inhibitor (ARPI) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) achieving optimal PSA response.",[331],"Metastatic Hormone-sensitive Prostate Cancer (mHSPC)","2026-06-18",{"date":269,"type":34},{"date":335,"type":34},"2025-10-27",{"date":337,"type":21},"2031-10",{"name":40,"class":41},{"id":340,"slug":341,"hasResults":12,"nctId":342,"briefTitle":343,"officialTitle":344,"acronym":345,"eligibilityCriteria":346,"healthyVolunteers":12,"sex":17,"minAge":347,"maxAge":348,"enrollmentInfo":349,"targetDuration":4,"studyType":163,"phases":4,"briefSummary":350,"conditions":351,"keywords":4,"overallStatus":104,"whyStopped":4,"lastUpdateSubmitDate":353,"lastUpdatePostDateStruct":354,"startDateStruct":356,"completionDateStruct":357,"leadSponsor":359,"locationsCount":42},"100641618","lesion-tailored-fundus-controlled-perimetry-in-geographic-atrophy-ga-100641618","NCT07582042","Lesion-tailored, Fundus-controlled Perimetry in Geographic Atrophy (GA).","Integration of Lesion-tailored, Fundus-controlled Perimetry Into Routine Clinical Care for Patients With Geographic Atrophy (GA) Receiving Pegcetacoplan Treatment in Accordance With the Approved Label.","FCPGA-2025","Inclusion Criteria:\n\n* Age 65-90 years.\n* Geographic Atrophy (GA) secondary to dry Age-related Macular Degeneration (AMD) in at least one eye with the following criteria:\n\n  * GA lesion size between 1 and 15 mm² (≈ 0.4 to 6 disc areas)\n  * GA borders must be at least 500 μm from the edge of the 30° × 25° optical coherence tomography (OCT) image frame\n  * No confluent GA extending into peripapillary atrophy\n* Receiving intravitreal pegcetacoplan per label (at least one injection before screening).\n* Best-corrected visual acuity (BCVA) of 0.1 - 1.0 logMAR (≈ 20\u002F20 to 20\u002F200 Snellen)\n* Able to undergo mesopic FCP and required imaging.\n* Informed consent provided.\n\nExclusion Criteria:\n\n* Currently or previously active exudative macular neovascularization in the study eye.\n* High refractive errors (\\> ±5.00 Diopters \\[D\\] spherical equivalent) and significant astigmatism (\\> 2.50 D).\n* Ocular comorbidities likely to confound sensitivity or imaging (e.g., diabetic retinopathy with macular edema, retinal vein occlusion (RVO), inherited retinal disease, uncontrolled glaucoma).\n* Media opacity precluding reliable fundus-controlled perimetry (FCP) or imaging (e.g., dense cataract, corneal opacity, vitreous hemorrhage).\n* Any systemic condition judged likely to compromise participation, follow-up, or data integrity.","65 Years","90 Years",{"count":52,"type":21},"The goal of this observational study is to evaluate changes in retinal sensitivity over time in patients with geographic atrophy due to age related macular degeneration who are receiving pegcetacoplan as part of routine clinical care. The study aims to determine whether lesion tailored fundus-controlled perimetry can reliably measure functional changes near areas of atrophy and whether this testing can be implemented in everyday clinic care over 24 months. Participants will undergo repeated vision testing, standard eye imaging, and visual function questionnaires while continuing their prescribed treatment.",[352],"Geographic Atrophy From Age-related Macular Degeneration","2026-06-15",{"date":355,"type":34},"2026-06-17",{"date":353,"type":34},{"date":358,"type":21},"2029-08-01",{"name":40,"class":41},{"id":361,"slug":362,"hasResults":12,"nctId":363,"briefTitle":364,"officialTitle":365,"acronym":366,"eligibilityCriteria":367,"healthyVolunteers":191,"sex":17,"minAge":368,"maxAge":369,"enrollmentInfo":370,"targetDuration":4,"studyType":22,"phases":372,"briefSummary":373,"conditions":374,"keywords":377,"overallStatus":104,"whyStopped":4,"lastUpdateSubmitDate":384,"lastUpdatePostDateStruct":385,"startDateStruct":387,"completionDateStruct":389,"leadSponsor":391,"locationsCount":392},"100549893","rural-adult-and-youth-sun-protection-study-100549893","NCT06439979","Rural Adult and Youth Sun Protection Study","Rural Adult and Youth Sun Protection Study - Rural Baseball R01","RAYS","Parent inclusion criteria:\n\ni. Adults who currently have children ages 3 and older years of age playing on participating sports teams in leagues serving rural areas in Utah or West Virginia (rural is defined as ≥4 by the RUCA or RUCC systems)\n\nii. Live and\u002For work in rural communities in Utah or West Virginia (≥4 as defined by the RUCA or RUCC systems)\n\nCoach\u002Fleader inclusion criteria:\n\ni. Adults who serve as coaches or leaders of recreational sports (i.e. baseball\u002Fsoftball, soccer, flag football, etc.) teams or developmental programs serving children ages 3 and older\n\nii. Live and\u002For work in rural areas of Utah or West Virginia (rural is defined as ≥4 by the RUCA or RUCC systems)\n\nParticipant inclusion criteria for minor participants (ages 3 and older) are as follows:\n\ni. Live in rural communities and\u002For participate in sports leagues serving rural communities in Utah or West Virginia (≥4 as defined by the RUCA or RUCC systems).\n\nParticipant inclusion criteria for key informant interviews are as follows:\n\ni. Adults who serve as leaders or who are affiliated with sports leagues or community groups serving rural youths and\u002For adults who currently have minor children 3 years of age or older playing on participating sports teams and\u002For adults who live and\u002For work in rural communities in Utah or West Virginia ((≥4 as defined by the RUCA or RUCC systems)\n\nLocal sports leagues will be eligible to participate if they convene recreational sports (i.e. baseball\u002Fsoftball) teams or developmental programs (i.e. T-ball and coach pitch) for children ages 3 and older.\n\nExclusion Criteria:\n\n* Adults and children who do not speak or read English will be excluded.\n* For individuals asked to complete surveys, individuals who have a medical or other condition (e.g., developmental delay) that would preclude their completion of these surveys will be excluded.","3 Years","7 Years",{"count":371,"type":21},843,[54],"The purpose of this study is to help prevent skin cancer by improving the use of sun protective behaviors among youths living in rural communities in Utah and West Virginia.",[375,376],"Melanoma (Skin)","Skin Cancer",[378,379,380,381,382,383],"Rural","Melanoma, Skin cancer","Prevention","Underserved communities","Youth","Sports","2026-06-10",{"date":386,"type":34},"2026-06-12",{"date":388,"type":34},"2024-04-08",{"date":390,"type":21},"2030-04",{"name":40,"class":41},2,{"id":394,"slug":395,"hasResults":12,"nctId":396,"briefTitle":397,"officialTitle":397,"acronym":4,"eligibilityCriteria":398,"healthyVolunteers":12,"sex":17,"minAge":50,"maxAge":399,"enrollmentInfo":400,"targetDuration":4,"studyType":22,"phases":402,"briefSummary":403,"conditions":404,"keywords":4,"overallStatus":104,"whyStopped":4,"lastUpdateSubmitDate":406,"lastUpdatePostDateStruct":407,"startDateStruct":408,"completionDateStruct":409,"leadSponsor":410,"locationsCount":42},"100642217","microvideos-for-improving-hpv-vaccination-among-childhood-cancer-survivors-100642217","NCT07648953","Microvideos for Improving HPV Vaccination Among Childhood Cancer Survivors","Inclusion Criteria:\n\n* Eligible participants include cancer survivors who are currently ages 18-26 years and who were diagnosed with childhood cancer (ages 0-26 at diagnosis) in the past ten years.\n* Currently use Facebook or willing to create a Facebook account to use for the duration of the study.\n* At the time of enrollment, have not completed all recommended doses of the HPV vaccine.\n\nExclusion Criteria:\n\n* Unable to speak and understand English.\n* Participants who take part in the Aim 1 focus groups will be ineligible for the Aim 2 social media group.\n* Participants who are fully vaccinated for HPV will be ineligible as the goal of Aim 2 is to evaluate the feasibility of the social media campaign for improving vaccine intention among HPV unvaccinated individuals.","26 Years",{"count":401,"type":21},55,[54],"This exploratory mixed-methods study aims to examine receipt of treatment and decision-making among rural cancer patients in Utah. Guided by Conceptual Model of Healthcare Access, the study will integrate, survey and cancer registry data with patient interviews to better understand how travel burden, socioeconomic conditions, health literacy, and other contextual factors shape treatment location and access to care . While the setting of this research is specific to Utah, a state with vast rural regions and only one National Cancer Institute (NCI)-designated cancer center, the findings may inform policy and practice improvements in other states with similar geographic and healthcare infrastructure. Thus, the study has potential relevance for advancing rural cancer equity nationwide.\n\nUnderstanding how rural cancer patients make treatment decisions is essential to addressing persistent disparities in cancer care access and outcomes. While geographic barriers and structural inequities are well-documented, less is known about the individual and contextual factors that shape patients' choices about where and how to receive treatment. This mixed-methods study will examine receipt of treatment, decision-making, and patient experience among rural cancer patients in Utah, with attention to travel burden, referral pathways, health literacy, and perceived barriers to care.",[405],"HPV Vaccination","2026-06-09",{"date":353,"type":34},{"date":86,"type":21},{"date":131,"type":21},{"name":40,"class":41},{"id":412,"slug":413,"hasResults":12,"nctId":414,"briefTitle":415,"officialTitle":416,"acronym":4,"eligibilityCriteria":417,"healthyVolunteers":12,"sex":17,"minAge":418,"maxAge":4,"enrollmentInfo":419,"targetDuration":4,"studyType":22,"phases":421,"briefSummary":422,"conditions":423,"keywords":425,"overallStatus":104,"whyStopped":4,"lastUpdateSubmitDate":406,"lastUpdatePostDateStruct":432,"startDateStruct":433,"completionDateStruct":435,"leadSponsor":437,"locationsCount":42},"100624069","scaling-up-building-healthy-families-100624069","NCT07404839","Scaling up Building Healthy Families","Scaling up Building Healthy Families in Rural Areas and Small Towns","Communities must respond to a call for proposals by submitting a letter of intent and a brief narrative describing the local need for BHF and readiness for implementation. Community eligibility for this trial includes:\n\n* Any community is eligible to apply for the competitive BHF RFA process;\n* BHF RFA scoring prioritizes community narratives that meet the following criteria: (1)Childhood obesity prevention and treatment are a priority health concern; (2) Communities and community-based organizations located in rural, frontier, or micropolitan areas, and\u002For that provide services to families from these areas; (3) Communities and community-based organizations that provide services or reach families in other low-resource contexts, such as areas with limited access to evidence-based health promotion and disease prevention\u002Ftreatment interventions.\n* The community is willing to be randomized to either study condition.\n* The community is willing to form a Community Implementation Team (CIT) to implement BHF.\n\nEligibility for Community Implementation Teams (CIT) includes:\n\n* Adults, age 18 years or older\n* Employed by or affiliated with the community-based organizations that applied and were selected through the bundled adoption strategy (i.e., LOI\u002FRFA) process.\n\nBHF Program Family Eligibility:\n\n* Must have at least one child between the ages of 5 and 13 years with a BMI at or above the 85th percentile;\n* One parent or caregiver must agree to attend BHF sessions with the child.","5 Years",{"count":420,"type":21},150,[54],"Evidence-based interventions for childhood obesity (EBI-CO) can improve children's weight status, but families in rural areas and small cities have limited access to the interdisciplinary healthcare teams recommended to deliver EBI-CO. To address this issue, the investigators adapted an EBI-CO, Building Healthy Families (BHF), which includes all materials and training resources necessary for rural program implementation. The pilot study found that when paired with opportunities to learn from the program developers and other community implementation teams, the packaged program led to effective delivery across 4 rural communities. This scale-up study will compare packaged BHF Resources with and without a learning collaborative facilitation strategy, examining outcomes including reach, effectiveness, implementation, and potential for sustainability in rural areas.",[424],"Obesity, Child",[426,427,428,429,430,431],"rural","implementation strategies","family based program","dissemination and implementation science","lifestyle change intervention","family based programs",{"date":384,"type":34},{"date":434,"type":34},"2025-11-01",{"date":436,"type":21},"2030-06-30",{"name":40,"class":41},{"id":439,"slug":440,"hasResults":12,"nctId":441,"briefTitle":442,"officialTitle":442,"acronym":4,"eligibilityCriteria":443,"healthyVolunteers":12,"sex":17,"minAge":50,"maxAge":4,"enrollmentInfo":444,"targetDuration":4,"studyType":22,"phases":445,"briefSummary":446,"conditions":447,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":449,"lastUpdatePostDateStruct":450,"startDateStruct":452,"completionDateStruct":454,"leadSponsor":456,"locationsCount":42},"100624519","safeai-developing-and-testing-an-ai-based-hybrid-chatbot-for-financial-empowerment-in-rural-cancer-care-100624519","NCT07410689","SAFE.AI: Developing and Testing an AI-based Hybrid Chatbot for Financial Empowerment in Rural Cancer Care","Inclusion Criteria:\n\n* Adults (18 years and older)\n* Cancer patients or financially responsible caregivers of cancer patients who:\n* Reside in the Huntsman Cancer Institute's five-state catchment area (Utah, Idaho, Wyoming, Montana, and Nevada),\n* Are able to read and write in English, and\n* Live in a rural area, defined by endorsement of a residential ZIP code classified as non-metropolitan (RUCA codes 4-10) per the USDA Rural-Urban Commuting Area Codes.\n\nExclusion Criteria:\n\n* Respondents who do not live within this 5-state region--The SAFE toolkit material was developed for the Huntsman Cancer Institute patient population which serves UT, ID, MT, WY, \\& NV\n* Respondents who only speak Spanish or other exclusively non-English speaking groups--The large language model for the chatbot will be developed in the English language. As non-English language training for the chatbot is not part of the scope of this study, participants who are unable to read and write in English may not be appropriate. As such, we will not be recruiting participants who only speak Spanish or other exclusively non-English speaking groups. Future studies will include adaptation of the chatbot to other languages.\n* Caregivers who are not primarily responsible for the financial aspects of patients' cancer care--The topic of financial hardship of cancer care may be less relevant for caregivers who are not financially involved in care.\n* Non-rural dwelling",{"count":74,"type":21},[54],"This is a randomized, two-arm, parallel-group pilot trial investigating a new chatbot tool designed to support cancer patients and caregivers, particularly those in rural communities. Approximately 60 participants will be randomized 1:1 to interact with either a hybrid chatbot or an AI-enabled chatbot. Participants will use their assigned chatbot to obtain clear and helpful information related to insurance, travel costs, and other financial aspects of cancer care.",[57,448],"Financial Toxicity","2026-06-04",{"date":451,"type":34},"2026-06-05",{"date":453,"type":21},"2026-06",{"date":455,"type":21},"2027-12",{"name":40,"class":41},{"id":458,"slug":459,"hasResults":12,"nctId":460,"briefTitle":461,"officialTitle":462,"acronym":463,"eligibilityCriteria":464,"healthyVolunteers":12,"sex":17,"minAge":50,"maxAge":4,"enrollmentInfo":465,"targetDuration":4,"studyType":22,"phases":467,"briefSummary":468,"conditions":469,"keywords":4,"overallStatus":104,"whyStopped":4,"lastUpdateSubmitDate":449,"lastUpdatePostDateStruct":472,"startDateStruct":473,"completionDateStruct":475,"leadSponsor":477,"locationsCount":42},"100470402","phase-2-impact-of-budesonide-on-incidence-of--gr2-diarrhea-in-multiple-myeloma-mm-patients-undergoing-autologous-stem-cell-transplant-100470402","NCT05405387","Impact of Budesonide on Incidence of ≥ Gr2 Diarrhea in Multiple Myeloma (MM) Patients Undergoing Autologous Stem Cell Transplant","A Randomized Phase 2 Trial Investigating the Impact of Budesonide Prophylaxis on Incidence of ≥ Grade 2 Diarrhea in Multiple Myeloma (MM) Patients Undergoing Autologous Stem Cell Transplant","IMPACT","Inclusion Criteria:\n\n* Subject aged ≥ 18 years.\n* History of histologically confirmed multiple myeloma and\u002For Plasma Cell Leukemia diagnosis undergoing ASCT who are determined to be fit by the investigator to undergo ASCT with melphalan 200 mg\u002Fm2 or melphalan 140 mg\u002Fm2 as conditioning.\n* Able to provide informed consent and willing to sign an approved consent form that conforms to federal and institutional guidelines.\n* Adequate organ function as defined as:\n\n  --Hepatic:\n  * Total Bilirubin ≤ 2 x institutional upper limit of normal (ULN).\n  * AST(SGOT)\u002FALT(SGPT) ≤ 5 × institutional ULN\n* For female subjects who have not undergone surgical sterilization: Negative pregnancy test or evidence of post-menopausal status. The post-menopausal status will be defined as having been amenorrheic for 12 months without an alternative medical cause or having undergone surgical sterilization (bilateral oophorectomy or hysterectomy). The following age-specific requirements apply:\n\n  * Women \\\u003C 50 years of age:\n\n    * Amenorrheic for ≥ 12 months following cessation of exogenous hormonal treatments; and\n    * Luteinizing hormone and follicle-stimulating hormone levels in the post-menopausal range for the institution; or\n    * Underwent surgical sterilization (bilateral oophorectomy or hysterectomy).\n  * Women ≥ 50 years of age:\n\n    * Amenorrheic for 12 months or more following cessation of all exogenous hormonal treatments; or\n    * Had radiation-induced menopause with last menses \\>1 year ago; or\n    * Had chemotherapy-induced menopause with last menses \\>1 year ago; or\n    * Underwent surgical sterilization (bilateral oophorectomy, bilateral salpingectomy, or hysterectomy).\n\nInclusion Criteria required for Patients Enrolling in Safety Run-In Cohort only:\n\n-Patient must have at least 2.5 x 106 CD34 cells in reserve for use if engraftment is delayed\n\nExclusion Criteria:\n\n* Ongoing or current use of oral budesonide at the time of enrollment.\n* Receiving other investigational agents, unless deemed acceptable after consultation with the PI\n* Subjects with moderate or severe pre-existing hepatic impairment as classified according to the Child-Pugh system.\n* Prior history or current diagnosis of inflammatory bowel disease, microscopic colitis at baseline.\n* Prior history of receiving an allogenic stem cell transplant\n* Medical, psychiatric, cognitive, or other conditions that may compromise the subject's ability to understand the subject information, give informed consent, comply with the study protocol or complete the study.\n* Known prior severe hypersensitivity to melphalan or budesonide or any component in their formulations or compounds of similar composition (NCI CTCAE v5.0 Grade ≥ 3).\n* Subjects taking prohibited medications as described in Section 6.6.1. A washout period of prohibited medications for a period of at least five half-lives or 14 days (whichever is shorter) should occur before the start of treatment.",{"count":466,"type":21},120,[100],"A randomized placebo controlled, phase 2 study of budesonide in subjects with multiple myeloma undergoing autologous stem cell transplant (ACST). The study includes a run-in period with 20 patients.",[470,471],"Multiple Myeloma","Plasma Cell Leukemia",{"date":451,"type":34},{"date":474,"type":34},"2023-05-03",{"date":476,"type":21},"2028-03",{"name":40,"class":41},{"id":479,"slug":480,"hasResults":12,"nctId":481,"briefTitle":482,"officialTitle":483,"acronym":484,"eligibilityCriteria":485,"healthyVolunteers":12,"sex":217,"minAge":50,"maxAge":4,"enrollmentInfo":486,"targetDuration":4,"studyType":22,"phases":488,"briefSummary":489,"conditions":490,"keywords":4,"overallStatus":104,"whyStopped":4,"lastUpdateSubmitDate":449,"lastUpdatePostDateStruct":496,"startDateStruct":497,"completionDateStruct":499,"leadSponsor":501,"locationsCount":42},"100452216","phase-2-cabozantinib-and-atezolizumab-for-the-treatment-of-metastatic-castration-resistant-prostate-cancer-100452216","NCT05168618","Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer","AtezoCab: A Phase II Study of Cabozantinib in Combination With Atezolizumab in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) With Non-Measurable Disease","AtezoCab","Inclusion Criteria:\n\n* Male subject aged \\>= 18 years\n* Histologically or cytologically confirmed prostatic adenocarcinoma without small cell histology\n* Metastatic disease progression after continuous androgen deprivation therapy for hormone sensitive state\n* Patient must have non-measurable disease outside the pelvis (above aortic bifurcation) per RECIST 1.1 criteria. Non-measurable disease can be bone lesions and\u002For extraskeletal disease\n* Disease progression on or after at least one prior novel hormonal therapy (NHT) (defined as second-generation antiandrogen therapies that include but are not limited to abiraterone acetate, enzalutamide, apalutamide, darolutamide)\n* Eastern Cooperative Oncology Group (ECOG) performance Status =\\\u003C 2\n* Effective castration with serum testosterone levels =\\\u003C 0.5 ng\u002FmL (=\\\u003C1.7 nmol\u002FL)\n* Tumor tissue available (archival or recent tumor biopsy). If no tumor tissue is available, patients can be enrolled after approval from Principal Investigator.\n* Absolute neutrophil count (ANC) \\>= 1500\u002Fmm\\^3 without granulocyte colony-stimulating factor support\n* White blood cell count \\>= 2500\u002FuL\n* Lymphocyte count \\>= 0.5 x 10\\^9\u002FL (500\u002FuL)\n* Platelet count \\>= 100,000\u002Fmm\\^3 without transfusion in the 2 weeks prior to cycle 1 day 1 (C1D1)\n* Hemoglobin \\>= 9 g\u002FdL\n* Serum albumin \\>= 2.5 g\u002Fdl\n* For patients not receiving therapeutic anticoagulation: prothrombin time (PT)\u002FInternational normalized ratio (INR) or partial thromboplastin time (PTT) test \\\u003C 1.5 x institutional upper limit of normal (ULN). For patients receiving therapeutic anticoagulation: stable anticoagulant regimen as determined by Investigator\n* Total bilirubin =\\\u003C 1.5 x institutional upper limit of normal (ULN). For subjects with Gilbert's disease =\\\u003C 3 x institutional ULN\n* Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase \\[SGOT\\]) and alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase \\[SGPT\\]) =\\\u003C 2.5 × institutional ULN\n\n  * Subjects with liver metastases will be allowed to enroll with AST and ALT levels =\\\u003C 5 x institutional ULN\n* Alkaline phosphatase (ALP) =\\\u003C 3 × institutional ULN. Patients with documented liver or bone metastases: ALP =\\\u003C 5 x institutional ULN\n* Serum creatinine =\\\u003C 1.5 x institutional ULN or calculated creatinine clearance \\>= 40 mL\u002Fmin by Cockcroft-Gault formula\n* Urine protein\u002Fcreatinine ration (UPCR) =\\\u003C 1mg\u002Fmg (=\\\u003C 113.2 mg\u002Fmmol), or 24-hour (h) urine protein =\\\u003C 1 g\n* Sexually active fertile subjects and their partners must agree to use medically accepted methods of contraception (e.g., barrier methods, including male condom, female condom, or diaphragm with spermicidal gel) during the course of the study and for 5 months after the last dose of study treatment\n* Male subjects must agree to use a condom during intercourse for the duration of study therapy\n* Recovery to baseline or =\\\u003C grade 1 Common Terminology Criteria for Adverse Events (CTCAE) v5.0 from toxicities related to any prior cancer therapy, unless considered clinically not significant by the treating investigator and\u002For stable on supportive therapy\n* Able to provide informed consent and willing to sign an approved consent form that conforms to federal and institutional guidelines\n* Capable of understanding and complying with the protocol requirements\n\nExclusion Criteria:\n\n* Prior chemotherapy in the metastatic castration refractory prostate cancer setting is not allowed (taxane-based in metastatic castration-sensitive disease is allowed)\n* Prior treatment with cabozantinib, CD137 agonists or immune checkpoint blockade therapies, including anti-CTLA-a, anti-PD1 and anti-PD-L1 therapeutic antibodies\n* Prior treatment with systemic immunostimulatory agents (including, but not limited to, interferon and interleukin 2 \\[IL-2\\]) within 4 weeks or 5 half-lives of the drug (whichever is longer) prior to initiation of study treatment\n* Receipt of any type of small molecule kinase inhibitor (including investigational kinase inhibitor) within 2 weeks before first dose of study treatment\n* Receipt of any type of cytotoxic, biologic or other systemic anticancer therapy (including investigational) within 4 weeks before first dose of study treatment\n* Receiving other investigational agents\n* Patients with measurable disease outside the pelvis (above aortic bifurcation) per RECIST 1.1 criteria\n* History of Leptomeningeal disease\n* Uncontrolled tumor-related pain\n\n  * Note: Patients requiring pain medication must be on a stable regimen at study entry\n  * Symptomatic lesions (e.g., bone metastases or metastases causing nerve impingement) amenable to palliative radiotherapy should be treated prior to enrollment. Patients should be recovered from the effects of radiation\n  * Asymptomatic metastatic lesions that would likely cause functional deficits or intractable pain with further growth (e.g., epidural metastasis that is not currently associated with spinal cord compression) should be considered for loco-regional therapy if appropriate prior to enrollment\n* Radiation therapy for bone metastasis within 2 weeks or any other radiation therapy within 4 weeks before first dose of study treatment. Systemic treatment with radionuclides within 6 weeks before first dose of study treatment. Subjects with clinically relevant ongoing complications from prior radiation therapy are not eligible\n* Major surgery (e.g., laparoscopic nephrectomy, gastrointestinal (GI) surgery, removal or biopsy of brain metastasis) within 4 weeks before first dose of study treatment or anticipation of need for a major surgical procedure during the study. Minor surgeries within 10 days before first dose of study treatment. Subjects must have complete wound healing from major surgery or minor surgery before first dose of study treatment. Subjects with clinically relevant ongoing complications from prior surgery are not eligible\n* Any other active malignancy at time of first dose of study treatment or diagnosis of another malignancy within 3 years prior to first dose of study treatment that requires active treatment, with the exception of malignancies with a negligible risk of metastasis or death (e.g., 5-year overall survival \\[OS\\] rate \\> 90%), such as locally curable cancers that have been apparently cured, such as basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the breast\n* Known brain metastases or cranial epidural disease\n\n  * Note: Brain metastases or cranial epidural disease adequately treated with radiotherapy and\u002For surgery (including radiosurgery) and stable for at least 4 weeks before the first dose of study treatment after radiotherapy or at least 4 weeks prior to the first dose of study treatment after major surgery (e.g. removal or biopsy of brain metastasis) will be allowed on trial. Subjects must have complete wound healing from major surgery or minor surgery before first dose of study treatment. Eligible subjects must be neurologically asymptomatic and without corticosteroid treatment at the time of the first dose of study treatment\n* Concomitant anticoagulation with coumarin agents (e.g., warfarin), direct thrombin inhibitors (e.g., dabigatran), direct factor Xa inhibitor betrixaban, or platelet inhibitors (e.g., clopidogrel). Allowed anticoagulants are the following:\n\n  * Prophylactic use of low-dose aspirin for cardio-protection (per local applicable guidelines), low-dose low molecular weight heparins (LMWH), or prophylactic dose of anticoagulation with direct factor Xa inhibitors rivaroxaban, edoxaban, or apixaban.\n  * Therapeutic doses of LMWH or anticoagulation with direct factor Xa inhibitors rivaroxaban, edoxaban, or apixaban in subjects without known brain metastases who are on a stable dose of the anticoagulant for at least 1 week before first dose of study treatment without clinically significant hemorrhagic complications from the anticoagulation regimen or the tumor\n* Administration of a live, attenuated vaccine (e.g., FluMist) within 30 days before first dose of any study treatment and for 5 months after the last dose of any study treatment\n* Current evidence of uncontrolled, significant intercurrent or recent illness including, but not limited to, the following conditions:\n\n  * Cardiovascular disorders:\n\n    * Congestive heart failure New York Heart Association Class II, III or IV, unstable angina pectoris, serious unstable cardiac arrhythmias\n    * Stroke (including transient ischemic attack \\[TIA\\]), myocardial infarction (MI), other ischemic events, or thromboembolic event (e.g., deep venous thrombosis, pulmonary embolism) within 6 months before the first dose of study treatment\n\n      * Subjects with a diagnosis of incidental, sub segmental PE or DVT within 6 months are allowed if stable, asymptomatic, and treated with a stable dose of permitted anticoagulation for at least 1 week before first dose of study treatment\n    * Uncontrolled hypertension defined as persistent systolic blood pressure (BP) \\> 150 mm Hg or diastolic BP \\> 90 mm Hg despite optimal antihypertensive treatment\n  * Gastrointestinal (GI) disorders including those associated with a high risk of perforation or fistula formation:\n\n    * The subject has evidence of tumor invading the GI tract, active peptic ulcer disease, inflammatory bowel disease (e.g., Crohn's disease), diverticulitis, cholecystitis, symptomatic cholangitis or appendicitis, acute pancreatitis, acute obstruction of the pancreatic duct or common bile duct, or gastric outlet obstruction\n    * Abdominal fistula, GI perforation, bowel obstruction, or intra-abdominal abscess within 6 months before first dose of study treatment. Note: Complete healing of an intra-abdominal abscess must be confirmed before first dose of study treatment\n  * Any other condition that would, in the Investigator's judgment, contraindicate the subject's participation in the clinical study due to safety concerns or compliance with clinical study procedures (e.g., infection\u002Finflammation, intestinal obstruction, unable to swallow medication, \\[subjects may not receive the drug through a feeding tube\\], social\u002F psychological issues, etc.)\n* Clinically significant hematuria, hematemesis, or hemoptysis of \\> 0.5 teaspoon (2.5 ml) of red blood, or other history of significant bleeding (e.g., pulmonary hemorrhage) within 12 weeks before first dose of study treatment\n* Cavitating pulmonary lesion(s) or known endotracheal or endobronchial disease manifestation\n* Lesions invading or encasing any major blood vessels\n* Any active or history of known or suspected autoimmune disease as determined to be clinically significant by treating investigator's clinical judgement will be excluded , including, but not limited to, myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, antiphospholipid antibody syndrome, Wegener granulomatosis, Sjogren syndrome, Guillain-Barre syndrome, or multiple sclerosis (see Appendix for a more comprehensive list of autoimmune diseases and immune deficiencies), with the following exceptions:\n\n  * Controlled Type 1 diabetes mellitus who are an insulin regimen\n  * Autoimmune-related hypothyroidism who are on thyroid replacement hormone\n  * Skin disorders (e.g., vitiligo, psoriasis, or alopecia) not requiring systemic treatment\n  * Patients with eczema, psoriasis, lichen simplex chronicus, or vitiligo with dermatologic manifestations only (e.g., patients with psoriatic arthritis are excluded) are eligible for the study provided all of following conditions are met:\n\n    * Rash must cover \\\u003C 10% of body surface area\n    * Disease is well controlled at baseline and requires only low potency topical corticosteroids\n    * No occurrence of acute exacerbations of the underlying condition requiring psoralen plus ultraviolet A radiation, methotrexate, retinoids, biologic agents, oral calcineurin inhibitors, or high potency or oral corticosteroids within the previous 12 months\n  * Conditions not expected to recur in the absence of an external trigger\n* Any condition requiring systemic treatment with either corticosteroids (\\> 10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days before first dose of study treatment, or anticipation of need for systemic immunosuppressive medication during study treatment, with the following exceptions:\n\n  * Patients who received acute, low-dose systemic immunosuppressant medication or a one-time pulse dose of systemic immunosuppressant medication (e.g., 48 hours of corticosteroids for a contrast allergy) are eligible for the study after Principal Investigator confirmation has been obtained\n  * Patients who received mineralocorticoids (e.g., fludrocortisone), corticosteroids for chronic obstructive pulmonary disease (COPD) or asthma, or low-dose corticosteroids for orthostatic hypotension or adrenal insufficiency are eligible for the study\n  * Note: Inhaled, intranasal, intra-articular, or topical steroids are permitted. Adrenal replacement steroid doses \\> 10 mg daily prednisone equivalent are permitted. Transient short-term use of systemic corticosteroids for allergic conditions (e.g., contrast allergy) is also allowed\n* Severe infection within 4 weeks prior to initiation of study treatment, including, but not limited to, hospitalization for complications of infection, bacteremia, or severe pneumonia\n* Any active infection requiring systemic treatment.\n\n  * Note: Patients receiving prophylactic antibiotics (e.g., to prevent a urinary tract infection or chronic obstructive pulmonary disease exacerbation) or oral valacyclovir (valaciclovir) are eligible for the study\n* Acute or chronic hepatitis B or C infection, known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)-related illness, or known positive test for tuberculosis infection where there is clinical or radiographic evidence of active mycobacterial infection. Note: Subjects on effective HIV antiretroviral therapy with an undetectable viral load within 6 months of the anticipated start of treatment are eligible for this trial\n* History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan\n* Serious non-healing wound\u002Fulcer\u002Fbone fracture\n* Malabsorption syndrome\n* Uncompensated\u002Fsymptomatic hypothyroidism\n* Moderate to severe hepatic impairment (Child-Pugh B or C)\n* Requirement for hemodialysis or peritoneal dialysis\n* History of solid organ or allogenic stem cell transplant\n* Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures (once monthly or more frequently)\n\n  * Note: Patients with indwelling catheters (e.g., PleurX) are allowed\n* Uncontrolled or symptomatic hypercalcemia (ionized calcium \\> 1.5 mmol\u002FL, calcium \\> 12 mg\u002FdL or corrected serum calcium \\> ULN)\n* Corrected QT interval calculated by the Fridericia formula (QTcF) \\> 500 ms per electrocardiogram (ECG) within 14 days before first dose of study treatment. Furthermore, subjects with a history of additional risk factors for Torsades de pointes (e.g., long QT syndrome) are also excluded.\n\n  * Note: If a single ECG shows a QTcF with an absolute value \\> 500 ms, two additional ECGs at intervals of approximately 3 min must be performed within 30 min after the initial ECG, and the average of these three consecutive results for QTcF will be used to determine eligibility.\n* Inability to swallow tablets or unwillingness or inability to receive IV administration\n* History of severe allergic anaphylactic reactions to chimeric or humanized antibodies or fusion proteins\n* Known hypersensitivity to Chinese hamster ovary cell products or to any component of the atezolizumab formulation\n* Previously identified allergy or hypersensitivity to components of the study treatment formulations or history of severe infusion-related reactions to monoclonal antibodies (NCI CTCAE v5.0 Grade ≥ 3). Subjects with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption are also excluded\n* Medical, psychiatric, cognitive, or other conditions that may compromise the subject's ability to understand the subject information, give informed consent, comply with the study protocol or complete the study\n* Subjects taking prohibited medications as described in Section 6. A washout period of prohibited medications for a period of at least five half-lives or as clinically indicated should occur before the start of treatment",{"count":487,"type":21},33,[100],"This phase II trial tests whether cabozantinib and atezolizumab work to shrink tumors in patients with castrate-resistant prostate cancer that had spread to other places in the body (metastatic). Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving cabozantinib and atezolizumab may kill more tumor cells in patients with metastatic castrate-resistant prostate cancer.",[491,492,493,494,495],"Castration-Resistant Prostate Carcinoma","Metastatic Prostate Adenocarcinoma","Stage IV Prostate Cancer AJCC v8","Stage IVA Prostate Cancer AJCC v8","Stage IVB Prostate Cancer AJCC v8",{"date":451,"type":34},{"date":498,"type":34},"2022-03-29",{"date":500,"type":21},"2027-01",{"name":40,"class":41},{"id":503,"slug":504,"hasResults":12,"nctId":505,"briefTitle":506,"officialTitle":507,"acronym":508,"eligibilityCriteria":509,"healthyVolunteers":12,"sex":17,"minAge":50,"maxAge":4,"enrollmentInfo":510,"targetDuration":4,"studyType":22,"phases":511,"briefSummary":512,"conditions":513,"keywords":4,"overallStatus":104,"whyStopped":4,"lastUpdateSubmitDate":514,"lastUpdatePostDateStruct":515,"startDateStruct":516,"completionDateStruct":518,"leadSponsor":520,"locationsCount":42},"100633566","phase-1-external-beam-radiotherapy-followed-by-bispecific-antibody-therapy-for-relapsedrefractory-dlbcl-100633566","NCT07528352","External Beam Radiotherapy Followed by Bispecific Antibody Therapy for Relapsed\u002FRefractory DLBCL","REBEL: A Phase 1b Study on the Safety and Feasibility of External Beam Radiotherapy Followed by Bispecific Antibody Therapy for Relapsed\u002FRefractory DLBCL","REBEL","Inclusion Criteria:\n\n* Participant aged ≥ 18 years\n* Disease criteria:\n\n  * Histologically confirmed large b-cell lymphoma (LBCL), including DLBCL not otherwise specified, including DLBCL arising from indolent lymphoma, and high-grade B-cell lymphoma with:\n  * Relapsed or refractory disease with at least 2 prior systemic therapies\n* Must be a candidate for radiation therapy up to 20 Gy. Radiation therapy to up to 3 lesions will be permitted.\n* Must have at minimum two sites of evaluable disease per Lugano 2014, including one site that will not be irradiated as part of this study and has not received radiation therapy in the past.\n* ECOG Performance Status ≤ 3\n* Adequate organ function as defined as\n\n  --Hematologic:\n  * Absolute neutrophil count ≥ 1000\u002Fmm3 (Note: Use of G-CSF is permitted)\n  * Platelet count ≥ 50,000\u002Fmm3 (Note: Use of platelet transfusions is permitted)\n  * Hemoglobin ≥ 7 g\u002FdL, (Note: Blood transfusions are permitted)\n\n    --Hepatic:\n  * Total Bilirubin ≤ 1.5x institutional upper limit of normal (ULN)\n  * AST(SGOT)\u002FALT(SGPT) ≤ 3 × institutional ULN ----Participants with liver metastases will be allowed to enroll with AST and ALT levels ≤ 5 x ULN.\n\n    --Renal:\n  * Estimated creatinine clearance ≥ 40 mL\u002Fmin by Cockcroft-Gault formula.\n* Participants must adhere to the following sex and contraceptive\u002Fbarrier requirements:\n\n  * If participant is of childbearing potential they must have a negative pregnancy test\n  * For participants of non-child bearing potential: The post-menopausal status will be defined as having been amenorrheic for 12 months without an alternative medical cause. The following age-specific requirements apply:\n  * \\\u003C 50 years of age: ---Amenorrheic for ≥ 12 months following cessation of exogenous hormonal treatments; and\n\n    * Luteinizing hormone and follicle-stimulating hormone levels in the post-menopausal range for the institution --≥ 50 years of age:\n    * Amenorrheic for 12 months or more following cessation of all exogenous hormonal treatments; or\n    * Had radiation-induced menopause with last menses \\>1 year ago; or\n    * Had chemotherapy-induced menopause with last menses \\>1 year ago\n    * Luteinizing hormone and follicle-stimulating hormone levels in the post-menopausal range for the institution\n  * Participants of childbearing potential and participants with a sexual partner of childbearing potential must agree to use a highly effective method of contraception and lactation requirements as described in Sections 5.4.1 and 5.4.2.\n* Clinically significant adverse effects from any prior oncologic treatment (e.g. prior surgery, radiotherapy, or other antineoplastic therapy) must have resolved or have been determined to be clinically stable per the Investigator.\n* Able to provide informed consent and willing to sign an approved consent form that conforms to federal and institutional guidelines.\n\nExclusion Criteria:\n\n* Currently receiving any other approved or investigational therapy considered as a treatment for lymphoma with the exception of corticosteroids.\n* Progressive disease on prior CD20 x CD3 bispecific antibody\n\n  --Note: Prior therapy with CD20 x CD3 bispecific antibody is allowed.\n* Prior systemic anti-cancer therapy which may have delayed treatment effects (e.g. immunotherapy) ≤ 14 days or within five half-lives prior to starting study treatment, whichever is shorter.\n* The diagnosis of another malignancy which, in the opinion of the Investigator, is likely to negatively impact the participant's safety or ability to participate in the study.\n* Known brain metastases or cranial epidural disease.\n\n  --Note: Brain metastases or cranial epidural disease adequately treated with radiotherapy and\u002For surgery and stable for at least 4 weeks before the first dose of study treatment will be allowed on trial. Participants must be neurologically stable and receiving a stable or decreasing corticosteroid dose at the time of study entry\n* Significant medical diseases or other conditions, as assessed by the investigator, that would substantially increase the risk-to-benefit ratio of participating in the study.\n* Active systemic bacterial, viral, fungal or other infection requiring systemic treatment at time of screening.\n* Known HIV infection with a detectable viral load within 6 months of the anticipated start of treatment.\n\n  --Note: Participants on effective antiretroviral therapy with an undetectable viral load within 6 months of the anticipated start of treatment are eligible for this trial.\n* Hepatitis B (known positive HBV surface antigen (HBsAg) result), or hepatitis C.\n\n  --Note: Participants with a past or resolved HBV infection (defined as the presence of hepatitis B core antibody \\[anti-HBc\\] and absence of HBsAg) are eligible. Participants positive for hepatitis C (HCV) antibody are eligible only if polymerase chain reaction is negative for HCV RNA.\n* Medical, psychiatric, cognitive, or other conditions that may compromise the participant's ability to understand the participant information, give informed consent, comply with the study protocol or complete the study.\n* Unable to tolerate corticosteroids\n* Participants taking prohibited medications as described in Section 6.6.1.",{"count":240,"type":21},[122],"The purpose of this clinical trial is to assess the safety and tolerability of ration therapy followed by receiving epcoritamab or glofitamab in patients with relapsed\u002Frefractory diffuse large B-cell lymphoma.",[126],"2026-06-02",{"date":449,"type":34},{"date":517,"type":34},"2026-06-01",{"date":519,"type":21},"2031-06",{"name":40,"class":41},{"id":522,"slug":523,"hasResults":12,"nctId":524,"briefTitle":525,"officialTitle":526,"acronym":527,"eligibilityCriteria":528,"healthyVolunteers":12,"sex":17,"minAge":50,"maxAge":4,"enrollmentInfo":529,"targetDuration":4,"studyType":22,"phases":531,"briefSummary":532,"conditions":533,"keywords":4,"overallStatus":104,"whyStopped":4,"lastUpdateSubmitDate":514,"lastUpdatePostDateStruct":535,"startDateStruct":536,"completionDateStruct":538,"leadSponsor":539,"locationsCount":42},"100480421","phase-1-allohct-with-peginfa-for-myelofibrosis-100480421","NCT05535764","AlloHCT With PegINFa for Myelofibrosis","Allogeneic Hematopoietic Cell Transplantation With Pegylated Interferon Alfa-2a for Primary and Secondary Myelofibrosis (ATIOM)","ATIOM","Inclusion Criteria:\n\nPre-Transplant Inclusion Criteria (Step 1)\n\n* Male or female subject aged ≥ 18 years.\n* Diagnosis of primary or secondary myelofibrosis.\n* Eligible to undergo a myeloablative or reduced intensity conditioning regimen (MAC or RIC)\n* Eligible to undergo a standard of care bone marrow biopsy with aspirate as part of his or her routine pre-transplant work-up.\n* Peripheral blood stem cell (PBSC) graft\n* 10\u002F10 HLA matched related or matched unrelated donor\n* ECOG performance status ≤ 2.\n* For female subjects: Negative pregnancy test or evidence of post-menopausal status. The post-menopausal status will be defined as having been amenorrheic for 12 months without an alternative medical cause. The following age-specific requirements apply:\n\n  * Women \\\u003C 50 years of age:\n\n    * Amenorrheic for ≥ 12 months following cessation of exogenous hormonal treatments; and\n    * Luteinizing hormone and follicle-stimulating hormone levels in the post-menopausal range for the institution; or\n    * Underwent surgical sterilization (bilateral oophorectomy or hysterectomy).\n  * Women ≥ 50 years of age:\n\n    * Amenorrheic for 12 months or more following cessation of all exogenous hormonal treatments; or\n    * Had radiation-induced menopause with last menses \\>1 year ago; or\n    * Had chemotherapy-induced menopause with last menses \\>1 year ago; or\n    * Underwent surgical sterilization (bilateral oophorectomy, bilateral salpingectomy, or hysterectomy).\n* Female subjects of childbearing potential and male subjects with a sexual partner of childbearing potential must agree to use a highly effective method of contraception as described in Section 5.4.1.\n\nTreatment Inclusion Criteria (Step 2)\n\n* Male or female subject aged ≥ 18 years.\n* Diagnosis of primary or secondary myelofibrosis.\n* Have undergone a myeloablative or reduced-intensity conditioning regimen (MAC or RIC) and be 50-80 days from Day 0 of transplant at initiation of study therapy.\n* Peripheral blood stem cell (PBSC) graft\n* 10\u002F10 HLA matched related or matched unrelated donor\n* ECOG Performance Status ≤ 2.\n* Adequate organ function as defined as:\n\n  * Hepatic:\n\n    * Total Bilirubin ≤ 1.5x institutional upper limit of normal (ULN)\n    * AST(SGOT)\u002FALT(SGPT) ≤ 3 × institutional ULN\n  * Renal:\n\n    ---Estimated creatinine clearance ≥ 30 mL\u002Fmin by Cockcroft-Gault formula:\n  * TSH and T4 within normal limits or adequately controlled thyroid function.\n* For female subjects: Negative pregnancy test or evidence of post-menopausal status. The post-menopausal status will be defined as having been amenorrheic for 12 months without an alternative medical cause. The following age-specific requirements apply:\n\n  * Women \\\u003C 50 years of age:\n\n    * Amenorrheic for ≥ 12 months following cessation of exogenous hormonal treatments; and\n    * Luteinizing hormone and follicle-stimulating hormone levels in the post-menopausal range for the institution; or\n    * Underwent surgical sterilization (bilateral oophorectomy or hysterectomy).\n  * Women ≥ 50 years of age:\n\n    * Amenorrheic for 12 months or more following cessation of all exogenous hormonal treatments; or\n    * Had radiation-induced menopause with last menses \\>1 year ago; or\n    * Had chemotherapy-induced menopause with last menses \\>1 year ago; or\n    * Underwent surgical sterilization (bilateral oophorectomy, bilateral salpingectomy, or hysterectomy).\n* Female subjects of childbearing potential and male subjects with a sexual partner of childbearing potential must agree to use a highly effective method of contraception as described in Section 5.4.1.\n* Male subjects must agree to use a condom during intercourse for the duration of study therapy as described in Section 5.4.1.\n* Recovery to baseline or ≤ Grade 1 CTCAE v5.0 from toxicities related to any prior cancer therapy, unless considered clinically not significant by the treating investigator.\n* Able to provide informed consent and willing to sign an approved consent form that conforms to federal and institutional guidelines.\n\nExclusion Criteria:\n\nExclusion Criteria (Step 2)\n\n* Receiving other investigational agents concurrently\n* Prior systemic anti-cancer therapy or any investigational therapy within five half-lives prior to starting study treatment.\n* Prior radiotherapy within 6 weeks prior to the first dose of study treatment.\n* Major surgery within 6 weeks prior to starting study drug or patients who have not fully recovered from major surgery.\n* The diagnosis of another malignancy within ≤ 2 years before study enrollment, except for those considered to be adequately treated with no evidence of disease or symptoms and\u002For will not require therapy during the study duration (i.e., basal cell or squamous cell skin cancer, carcinoma in situ of the breast, bladder or of the cervix, or low-grade prostate cancer with Gleason Score ≤ 6).\n* Current evidence of uncontrolled, significant intercurrent illness including, but not limited to, the following conditions:\n\n  * Graft-versus-host disease:\n\n    ---Acute or chronic\n  * Cardiovascular disorders:\n\n    * Congestive heart failure New York Heart Association Class III or IV, unstable angina pectoris, serious cardiac arrhythmias.\n    * Stroke (including transient ischemic attack \\[TIA\\]), myocardial infarction (MI), or other ischemic events, or thromboembolic event (eg, deep venous thrombosis, pulmonary embolism) within 3 months before the first dose.\n    * QTc prolongation defined as a QTcF \\> 500 ms.\n    * Known congenital long QT.\n    * Left ventricular ejection fraction \\\u003C 55%.\n    * Uncontrolled hypertension defined as ≥ 140\u002F90 as assessed from the mean of three consecutive blood pressure measurements taken over 10 minutes.\n  * Any other condition that would, in the Investigator's judgment, contraindicate the subject's participation in the clinical study due to safety concerns or compliance with clinical study procedures (e.g., infection\u002Finflammation, intestinal obstruction, unable to swallow medication, \\[subjects may not receive the drug through a feeding tube\\], social\u002F psychological issues, etc.)\n* Active infection including HIV, tuberculosis (clinical evaluation that includes clinical history, physical examination, radiographic findings, and TB testing in line with local practice) or hepatitis C.\n\n  --Note: Subjects with a past or resolved HBV infection (defined as the presence of hepatitis B core antibody \\[anti-HBc\\] and absence of HBsAg) are eligible.\n* Autoimmune hepatitis or decompensated hepatic disease\n* Medical, psychiatric, cognitive, or other conditions that may compromise the subject's ability to understand the subject information, give informed consent, comply with the study protocol or complete the study.\n* Known prior severe hypersensitivity to investigational product (IP) or any component in its formulations (NCI CTCAE v5.0 Grade ≥ 3).\n* Subjects taking prohibited medications as described in Section 6.5.1. A washout period of prohibited medications for a period of at least five half-lives or as clinically indicated should occur before the start of treatment.\n* History of neuropsychiatric disease, autoimmune disease, or pancreatitis.\n* Presence of active interstitial lung disease or pneumonitis, bronchiolitis obliterans, pulmonary hypertension, ulcerative and hemorrhagic\u002Fischemic colitis, and ophthalmologic disorders.",{"count":530,"type":21},18,[122],"This is a single site, open-label, dose de-escalation, Phase 1 study of pegylated interferon alfa-2a administered after alloHCT in subjects with primary or secondary myelofibrosis. Part 1 of the study will assess the rate of dose-limiting toxicities (DLTs) during the DLT evaluation period and identify the Recommended Phase 2 Dose (RP2D). Once the RP2D is identified, 6 additional patients will be enrolled in the expansion cohort.",[534],"Myelofibrosis",{"date":449,"type":34},{"date":537,"type":34},"2023-08-02",{"date":476,"type":21},{"name":40,"class":41},{"id":541,"slug":542,"hasResults":12,"nctId":543,"briefTitle":544,"officialTitle":544,"acronym":545,"eligibilityCriteria":546,"healthyVolunteers":12,"sex":17,"minAge":50,"maxAge":4,"enrollmentInfo":547,"targetDuration":4,"studyType":22,"phases":549,"briefSummary":550,"conditions":551,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":517,"lastUpdatePostDateStruct":553,"startDateStruct":555,"completionDateStruct":556,"leadSponsor":558,"locationsCount":42},"100637102","llm-intervention-for-tobacco-in-underserved-populations-lift-up-100637102","NCT07620301","LLM Intervention for Tobacco in Underserved Populations (LIFT-UP)","LIFT-UP","Inclusion Criteria:\n\n* 18+ years old\n* Use ≥3 cigarettes\u002Fday on average\n* Motivated to quit in the next 30 days\n* Have a computer or tablet with internet access for 1:1 interviews\n* Speak English or Spanish\n* Home address is in an area characterized by persistent poverty\n\nExclusion Criteria:\n\n* None",{"count":548,"type":21},22,[54],"This study will test a tailored, multilingual tobacco cessation chatbot called LIFT-UP (LLM Intervention for Tobacco in Underserved Populations), designed to better meet the needs of people living in persistent poverty census tracts.\n\nThis study will use 1:1 semi-structured interviews to explore social drivers of health impacting TC, as well as digital access and preferences among those living in PPCTs. This qualitative approach enables guided yet flexible exploration of key domains while capturing unanticipated insights relevant to refining the chatbot.",[552],"Smoking Cessation",{"date":554,"type":34},"2026-06-03",{"date":517,"type":21},{"date":557,"type":21},"2027-05-31",{"name":40,"class":41},{"id":560,"slug":561,"hasResults":12,"nctId":562,"briefTitle":563,"officialTitle":564,"acronym":565,"eligibilityCriteria":566,"healthyVolunteers":12,"sex":217,"minAge":50,"maxAge":4,"enrollmentInfo":567,"targetDuration":4,"studyType":22,"phases":569,"briefSummary":571,"conditions":572,"keywords":4,"overallStatus":104,"whyStopped":4,"lastUpdateSubmitDate":517,"lastUpdatePostDateStruct":574,"startDateStruct":575,"completionDateStruct":577,"leadSponsor":579,"locationsCount":42},"100524765","phase-3-creatine-supplementation-and-resistance-training-to-preserve-muscle-mass-and-attenuate-cancer-progression-100524765","NCT06112990","Creatine Supplementation and Resistance Training to Preserve Muscle Mass and Attenuate Cancer Progression","Creatine Supplementation and Resistance Training to Preserve Muscle Mass and Attenuate Cancer Progression: A Double-Blind Randomized Controlled Trial","CREATINE-52","Inclusion Criteria:\n\n* Subject age ≥ 18 years old.\n* Metastatic castration-sensitive prostate cancer patients who have not met criteria for disease progression (per Prostate Cancer Working Group guidelines) on current systemic therapy\n* Currently treated with surgical castration or medical castration with Gonadotropin-releasing hormone (GnRH) agonists\u002Fantagonists, and\u002For an androgen receptor pathway inhibitor (ARPI)) aka novel hormone therapy (e.g., abiraterone, enzalutamide, apalutamide, darolutamide). Must have started the current regimen at least 12 weeks prior to enrollment.\n* Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 2\n* Not currently adhering to national physical activity guidelines for resistance training, as defined as participating in structured resistance training (e.g., time set aside in your day to workout) ≥ two days per week.\n* Regular access to an electronic device with internet service and ability for video calls (e.g., computer, smart phone, iPad, tablet, etc).\n* Access to an active MyChart account or the willingness to create an account for the purposes of the trial.\n* Willingness to engage in a home-based resistance exercise program two days per week.\n* Willingness to take creatine monohydrate supplementation or placebo for the duration of the 52 week trial and to avoid taking additional creatine-containing supplementation or other nutritional supplementation during the study period.\n* Willingness to complete and submit weekly supplementation logs to study personnel throughout the duration of the 52-week study via email, text, in person, or verbally verified over the phone.\n* Willingness to complete three in-person assessment sessions (baseline, 24-, and 52-weeks).\n* Able to provide informed consent and willing to sign an approved consent form that conforms to federal and institutional guidelines.\n\nExclusion Criteria:\n\n* Treatment with cytotoxic chemotherapy within 12 weeks prior to enrollment.\n* Estimated Glomerular Filtration Rate (eGFR) \\\u003C 30 ml\u002Fmin\u002F1.73m2.\n* ECOG Performance Status ≥ 3",{"count":568,"type":21},200,[570],"PHASE3","The goal of this clinical trial is to test the use of creatine monohydrate supplementation with resistance training to preserve muscle mass and help lessen prostate cancer progression.\n\nThe main question it aims to answer is if this treatment will help maintain muscle mass to help in reducing fatigue and improving physical function, independence, and quality of life.\n\nParticipants will be asked to participate in a 52-week exercise intervention consisting of a twice weekly telehealth resistance training program.",[573],"Metastatic Prostate Cancer",{"date":554,"type":34},{"date":576,"type":34},"2023-11-09",{"date":578,"type":21},"2028-11-30",{"name":40,"class":41},""]